


<OAI-PMH xmlns="http://www.openarchives.org/OAI/2.0/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"
         xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/ http://www.openarchives.org/OAI/2.0/OAI-PMH.xsd">
    <responseDate>2025-09-09T13:52:35Z</responseDate>
    <request verb="GetRecord" identifier="oai:pubmedcentral.nih.gov:12406249" metadataPrefix="pmc">https://pmc.ncbi.nlm.nih.gov/api/oai/v1/mh/</request>
    
    <GetRecord>
        <record>
    <header>
    <identifier>oai:pubmedcentral.nih.gov:12406249</identifier>
    <datestamp>2025-09-04</datestamp>
    
        
        <setSpec>pmc-open</setSpec>
        
    
</header>
    <metadata>
        
        <article xmlns="https://jats.nlm.nih.gov/ns/archiving/1.4/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xsi:schemaLocation="https://jats.nlm.nih.gov/ns/archiving/1.4/ https://jats.nlm.nih.gov/archiving/1.4/xsd/JATS-archivearticle1-4.xsd" xml:lang="en" id="i5841427" article-type="research-article" dtd-version="1.4"><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">Mol Pharm</journal-id><journal-id journal-id-type="iso-abbrev">Mol Pharm</journal-id><journal-id journal-id-type="pmc-domain-id">822</journal-id><journal-id journal-id-type="pmc-domain">acssd</journal-id><journal-id journal-id-type="publisher-id">mp</journal-id><journal-title-group><journal-title>Molecular Pharmaceutics</journal-title></journal-title-group><issn pub-type="ppub">1543-8384</issn><issn pub-type="epub">1543-8392</issn><self-uri>pubs.acs.org/molecularpharmaceutics</self-uri><custom-meta-group><custom-meta><meta-name>pmc-is-collection-domain</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-collection-title</meta-name><meta-value>ACS AuthorChoice</meta-value></custom-meta></custom-meta-group></journal-meta><article-meta><article-id pub-id-type="pmcid">PMC12406249</article-id><article-id pub-id-type="pmcid-ver">PMC12406249.1</article-id><article-id pub-id-type="pmcaid">12406249</article-id><article-id pub-id-type="pmcaiid">12406249</article-id><article-id pub-id-type="pmid">40772589</article-id><article-id pub-id-type="doi">10.1021/acs.molpharmaceut.5c00358</article-id><article-version article-version-type="pmc-version">1</article-version><article-categories><subj-group subj-group-type="heading"><subject>Article</subject></subj-group></article-categories><title-group><article-title>Hinge
Truncation to Improve Aggregation Kinetics and
Thermal Stability of an Antibody Fab Fragment</article-title></title-group><contrib-group id="CONTRIB-GROUP-d14e23-autogenerated"><contrib id="ath1" contrib-type="author"><contrib-id contrib-id-type="paragon-plus" authenticated="true">3176941</contrib-id><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0003-4406-2046</contrib-id><name name-style="western"><surname>Zhang</surname><given-names initials="C">Cheng</given-names></name><xref rid="aff1" ref-type="aff"/></contrib><contrib id="ath2" contrib-type="author"><contrib-id contrib-id-type="paragon-plus" authenticated="true">4885902</contrib-id><name name-style="western"><surname>Karu</surname><given-names initials="K">Kersti</given-names></name><xref rid="aff2" ref-type="aff"/></contrib><contrib id="ath3" contrib-type="author" corresp="yes"><contrib-id contrib-id-type="paragon-plus" authenticated="true">346691</contrib-id><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0002-0980-8167</contrib-id><name name-style="western"><surname>Dalby</surname><given-names initials="PA">Paul A.</given-names></name><xref rid="cor1" ref-type="corresp"/><xref rid="aff1" ref-type="aff"/></contrib><aff id="aff1">
<label>&#8224;</label>
<institution content-type="dept">Department
of Biochemical Engineering</institution>, <institution-wrap><institution-id institution-id-type="Ringgold" specific-use="source:pplus">4919</institution-id><institution>University College
London</institution></institution-wrap>, <addr-line>Gower Street</addr-line>, <city>London</city>
<postal-code>WC1E
6BT</postal-code>, <country country="GB">U.K.</country>
</aff><aff id="aff2">
<label>&#8225;</label>
<institution content-type="dept">Department
of Chemistry</institution>, <institution>University College London</institution>, <addr-line>20 Gordon Street</addr-line>, <city>London</city>
<postal-code>WC1H 0AJ</postal-code>, <country country="GB">U.K.</country>
</aff></contrib-group><author-notes><corresp id="cor1"><label>*</label>Email: <email>p.dalby@ucl.ac.uk</email>.</corresp></author-notes><pub-date date-type="pub" publication-format="electronic"><day>07</day><month>8</month><year>2025</year></pub-date><pub-date date-type="collection" publication-format="electronic"><day>01</day><month>9</month><year>2025</year></pub-date><volume>22</volume><issue>9</issue><issue-id pub-id-type="pmc-issue-id">496131</issue-id><fpage>5389</fpage><lpage>5399</lpage><history><date date-type="received"><day>18</day><month>3</month><year>2025</year></date><date date-type="accepted"><day>01</day><month>8</month><year>2025</year></date><date date-type="rev-recd"><day>14</day><month>7</month><year>2025</year></date><date date-type="online"><day>07</day><month>8</month><year>2025</year></date></history><pub-history><event event-type="pmc-release"><date><day>03</day><month>09</month><year>2025</year></date></event><event event-type="pmc-live"><date><day>04</day><month>09</month><year>2025</year></date></event><event event-type="pmc-last-change"><date iso-8601-date="2025-09-04 10:25:45.023"><day>04</day><month>09</month><year>2025</year></date></event></pub-history><permissions><copyright-statement>&#169; 2025 The Authors. Published by American Chemical Society</copyright-statement><copyright-year>2025</copyright-year><copyright-holder>The Authors</copyright-holder><ali:free_to_read content-type="AuthorChoicev2" start_date="2025-08-07"/><license><ali:license_ref specific-use="textmining" content-type="ccbylicense" start_date="2025-08-07">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>This article is licensed under CC-BY 4.0</license-p></license></permissions><self-uri content-type="pmc-pdf" xlink:href="mp5c00358.pdf"/><abstract><p>The hinge region
of antibody fragments plays a crucial
role in
their stability and aggregation properties. In this study, we investigated
the effects of hinge truncations on the thermal stability and aggregation
propensity of the A33 Fab antibody fragment. Eight Fab variants were
engineered by introducing stop codons to truncate 1&#8211;8 residues
at the hinge region (heavy chain residues 221&#8211;228). These variants
were then expressed, purified, and characterized in terms of stability
and aggregation propensity using SDS-PAGE, SEC-HPLC, LC&#8211;MS,
and thermal stability assays. Our findings demonstrate that truncating
the hinge region can enhance the thermal stability and reduce the
aggregation of Fab fragments, and that progressive truncations identified
an optimal hinge length for stability. Notably, the 227TGA variant
exhibited a significant 14.5% reduction in aggregation rate compared
to the wild type, without compromising thermal stability. By contrast,
221TGA removed all of the hinge and reduced the aggregation rate by
13%, but also decreased the thermal stability. These results suggest
that hinge truncation is a promising strategy for improving the developability
of therapeutic antibody Fab fragments by mitigating some of the stability
issues associated with aggregation.</p></abstract><abstract abstract-type="graphical"><graphic position="float" orientation="portrait" xlink:href="mp5c00358_0012.jpg"/></abstract><abstract abstract-type="toc-graphic"><graphic id="tgr1" position="float" orientation="portrait" xlink:href="mp5c00358_0010.jpg"/></abstract><kwd-group><kwd>hinge</kwd><kwd>truncation</kwd><kwd>stability</kwd><kwd>aggregation</kwd><kwd>engineering</kwd><kwd>therapeutic</kwd></kwd-group><funding-group><award-group id="fnd-1"><funding-source><institution-wrap><institution>Engineering and Physical Sciences Research Council</institution><institution-id institution-id-type="doi" vocab="open-funder-registry" vocab-identifier="10.13039/open_funder_registry">10.13039/501100000266</institution-id></institution-wrap></funding-source><award-id>EP/I033270/1</award-id></award-group></funding-group><funding-group><award-group id="fnd-2"><funding-source><institution-wrap><institution>Engineering and Physical Sciences Research Council</institution><institution-id institution-id-type="doi" vocab="open-funder-registry" vocab-identifier="10.13039/open_funder_registry">10.13039/501100000266</institution-id></institution-wrap></funding-source><award-id>EP/P006485/1</award-id></award-group></funding-group><custom-meta-group><custom-meta><meta-name>pmc-status-qastatus</meta-name><meta-value>0</meta-value></custom-meta><custom-meta><meta-name>pmc-status-live</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-status-embargo</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-status-released</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-open-access</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-olf</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-manuscript</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-legally-suppressed</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-pdf</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-supplement</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-pdf-only</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-suppress-copyright</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-real-version</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-scanned-article</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-preprint</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-in-epmc</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>document-id-old-9</meta-name><meta-value>mp5c00358</meta-value></custom-meta><custom-meta><meta-name>document-id-new-14</meta-name><meta-value>mp5c00358</meta-value></custom-meta><custom-meta><meta-name>production-flag-MathML-config-version</meta-name><meta-value>3</meta-value></custom-meta><custom-meta><meta-name>production-flag-journal-citation-display-style</meta-name><meta-value>acs-titles</meta-value></custom-meta><custom-meta><meta-name>production-flag-journal-date-display-style</meta-name><meta-value>dates-used-rcd-rvd-acc</meta-value></custom-meta><custom-meta><meta-name>production-flag-si-avail</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>document-id-alt-64</meta-name><meta-value>2912c1d74965fc9658c0d5fd2c49db6dfff3c2e869c309d0b54a89cbb7e150ba</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="sec1"><title>Introduction</title><p>Antibodies are integral to a wide array
of therapeutic and diagnostic
applications, necessitating a focus on their stability as a critical
aspect of biochemical engineering.<named-content content-type="bibref-group">
<xref rid="ref1" ref-type="bibr"/>&#8722;<xref rid="ref2" ref-type="bibr" specific-use="suppress-in-print"/>
<xref rid="ref3" ref-type="bibr"/>
</named-content> The challenges of aggregation
and thermal degradation continue to impact their therapeutic efficacy
and shelf life, despite substantial research efforts.<named-content content-type="bibref-group">
<xref rid="ref4" ref-type="bibr"/>,<xref rid="ref5" ref-type="bibr"/>
</named-content> This has led to various engineering strategies aimed at enhancing
their physical stability, including genetic mutations,<named-content content-type="bibref-group">
<xref rid="ref6" ref-type="bibr"/>,<xref rid="ref7" ref-type="bibr"/>
</named-content> the introduction of stabilizing disulfide bonds,<named-content content-type="bibref-group">
<xref rid="ref8" ref-type="bibr"/>,<xref rid="ref9" ref-type="bibr"/>
</named-content> and
modifications to glycosylation patterns,<named-content content-type="bibref-group">
<xref rid="ref10" ref-type="bibr"/>,<xref rid="ref11" ref-type="bibr"/>
</named-content> which aim to improve the molecule&#8217;s robustness while balancing
the potential impacts on its binding affinity and overall function.</p><p>One common method involves the strategic mutation of amino acids
within the antibody structure, often targeting the complementarity-determining
regions (CDR)<named-content content-type="bibref-group">
<xref rid="ref12" ref-type="bibr"/>&#8722;<xref rid="ref13" ref-type="bibr" specific-use="suppress-in-print"/>
<xref rid="ref14" ref-type="bibr"/>
</named-content> or other strategic sites to decrease aggregation
propensity without negatively affecting antigen-binding affinity.<named-content content-type="bibref-group">
<xref rid="ref15" ref-type="bibr"/>,<xref rid="ref16" ref-type="bibr"/>
</named-content> While beneficial, these mutations require careful design to avoid
detrimental impacts on antibody functionality. Additionally, enhancing
the structural integrity of antibodies through additional disulfide
bonds aims to stabilize the protein conformation, thus reducing the
likelihood of unfolding and subsequent aggregation under physiological
conditions.<xref rid="ref17" ref-type="bibr"/> However, this can sometimes
alter the molecular structure in ways that impair binding or modify
its immunogenic profile.<xref rid="ref18" ref-type="bibr"/> Beyond these
methods, other engineering techniques include altering the glycosylation
pattern of antibodies to improve stability and reduce aggregation.<xref rid="ref19" ref-type="bibr"/> While effective, these approaches often require
complex biotechnological manipulations and may not be universally
applicable across all antibody types.</p><p>Hinge deletion for a full
antibody has been shown previously to
reduce effector functions but also slightly decrease stability,<xref rid="ref20" ref-type="bibr"/> yet the impact of hinge truncation in Fab fragments
remains underexplored. While hinge flexibility is crucial for enabling
domain movement and optimal orientation between Fab and Fc for effective
antigen binding and effector function in full antibodies, it is not
required in the Fab format.</p><p>Fabs are frequently utilized independently
in therapeutic settings
due to their smaller size and unique binding properties.<xref rid="ref21" ref-type="bibr"/> The A33 antibody Fab fragment, which has been
extensively studied, characterized and structurally resolved in prior
research,<named-content content-type="bibref-group">
<xref rid="ref22" ref-type="bibr"/>&#8722;<xref rid="ref23" ref-type="bibr" specific-use="suppress-in-print"/>
<xref rid="ref24" ref-type="bibr"/>
</named-content> serves as an ideal model protein in this investigation
due to its well-documented structural properties and the known flexibility
of its hinge region. It consists of a light chain (LC) and a heavy
chain (HC) as shown in <xref rid="fig1" ref-type="fig">Figure <xref rid="fig1" ref-type="fig"/>
</xref>. The LC contains 214 residues (LC 1&#8211;214), and the
HC contains 228 residues (HC 1&#8211;228), with its C-terminus linked
to the hinge region of a full IgG antibody. Recent studies have highlighted
the flexibility of the HC C-terminus (referred as &#8220;hinge region&#8221;
here for brevity),<xref rid="ref25" ref-type="bibr"/> and have shown that
mutations in this area can decrease aggregation by up to 12% compared
to the wild type.<xref rid="ref26" ref-type="bibr"/> These stabilizing mutations
were associated with a significant increase in van&#8217;t Hoff entropy
change (&#916;<italic toggle="yes">S</italic>
<sub>vh</sub>), suggesting reduced
conformational flexibility and entropy in the native ensemble. Consequently,
we hypothesized that an alternative strategy to rigidify the hinge
region and reduce aggregation could be to partially truncate it, which
not only shortens the HC C-terminus but also potentially minimizes
disruption to adjacent residues. Since the hinge region is remote
from the Fab CDR binding domain, careful truncation is unlikely to
compromise the molecular integrity or binding affinity. In this study,
we truncated 1&#8211;8 residues at the 8-residue HC hinge region
(residues 221&#8211;228, or 217&#8211;224 Kabat) using a &#8220;TGA&#8221;
stop codon, creating eight Fab variants with progressively shortened
hinges. It is important to note that an interchain disulfide bond
exists between LC214 and HC220. The 221TGA variant could potentially
expose this disulfide bond to the solvent, increasing the likelihood
of incorrect cysteine pairing and resulting in Fab&#8211;Fab dimer
formation.</p><fig position="float" id="fig1" fig-type="figure" orientation="portrait"><label>1</label><caption><p>Structure of A33 Fab with modifications at the hinge region. Light
chain (green) and heavy chain (cyan) are depicted in cartoon format.
The five disulfide bonds are represented in sticks and colored yellow,
with the interchain disulfide bond between LC214 and HC220 indicated
by an arrow. Residues 221&#8211;228 of the heavy chain, highlighted
in red and also indicated by an arrow, are progressively truncated
from 1 to 8 residues to create eight variant structures with a shortened
hinge region.</p></caption><graphic id="gr1" position="float" orientation="portrait" xlink:href="mp5c00358_0001.jpg"/></fig></sec><sec id="sec2"><title>Materials and Methods</title><sec id="sec2.1"><title>In Vitro Site-Directed
Mutagenesis</title><p>The in vitro site-directed
mutagenesis and transformation was carried out as previously reported.<xref rid="ref26" ref-type="bibr"/> The QuikChange II XL Site-Directed Mutagenesis
Kit (Agilent Technologies, USA) was employed for site-directed mutagenesis,
after which the modified plasmids were introduced into One Shot TOP10
chemically competent <italic toggle="yes">E. coli</italic> (Thermo
Fisher Scientific, UK) and cultivated on Tet + LB agar plates. Individual
colonies were selected to extract and sequence plasmids. After confirming
the plasmid sequences, they were reintroduced into W3110 <italic toggle="yes">E. coli</italic> strains, and glycerol stocks were created
for future fermentation processes.</p><p>Stop codon TGA was used to
truncate 1&#8211;8 residues at the hinge region of heavy chain, resulting
in eight Fab variants with reduced lengths, and were named 228TGA,
227TGA, 226TGA, 225TGA, 224TGA, 223TGA, 222TGA, 221TGA, respectively.
The mutations were verified by DNA sequencing from Source BioScience
(Nottingham, UK). The amino acids and DNA sequences for the wild type
Fab are shown in the <ext-link xlink:href="https://pubs.acs.org/doi/suppl/10.1021/acs.molpharmaceut.5c00358/suppl_file/mp5c00358_si_001.pdf" ext-link-type="uri">Supporting Information</ext-link>, with the mutational positions highlighted.</p></sec><sec id="sec2.2"><title>Fab Expression, Purification,
and Buffer Exchange</title><p>The
procedures for Fab expression from the pTTOD plasmid in <italic toggle="yes">E. coli</italic> strain W3110, with SM6G defined media, 112
g/L glycerol and 10 &#956;g/mL tetracycline at 30 &#176;C, and purification
followed established methods,<xref rid="ref26" ref-type="bibr"/> utilizing
4 &#215; 250 mL DASbox Mini Bioreactor (Hamburg, Germany) and a Protein
G chromatography column on an &#196;KTA Explorer System (GE Healthcare,
Buckinghamshire, UK). Tight control with established protocols for
this production train ensured consistency with previous studies of
the same Fab. Formulations of Fab were prepared and stabilized at
4 &#176;C a day before conducting aggregation kinetics and thermal
stability tests. Samples of Fab, previously frozen at &#8722;80 &#176;C,
were thawed and passed through Anotop 25 0.02 &#956;m syringe filters
(GE Healthcare, Buckinghamshire, UK) to eliminate aggregates. The
samples were then subjected to buffer exchange with Milli-Q water,
concentrated to 2 mg/mL using 30 kDa cutoff Vivaspins (Generon Ltd.,
Berkshire, UK), and maintained at 4 &#176;C for storage.</p></sec><sec id="sec2.3"><title>Sodium Dodecyl
Sulfate-Polyacrylamide Gel Electrophoresis</title><p>SDS-PAGE was performed
to analyze the Fab protein samples under
both nonreducing and reducing conditions. The samples were prepared
at a concentration of 2 mg/mL in water. For nonreducing conditions,
10 &#956;L of the Fab solution was mixed with 5 &#956;L of 4&#215;
loading buffer and 5 &#956;L of water; for reducing conditions, 10
&#956;L of the Fab solution was combined with 5 &#956;L of 4&#215;
loading buffer and 5 &#956;L of 0.2 M dithiothreitol (DTT). Both
sample types were subsequently heated at 90&#8211;95 &#176;C for
15 min and then centrifuged briefly to collect the insoluble material
at the bottom of the tube.</p><p>The prepared samples were loaded
onto a 4&#8211;12% polyacrylamide gradient Bis-Tris gel (NuPAGE,
NP0322BOX) using a 12-well configuration. The gradient gel ensures
good resolution of species from potential fragments through to aggregate
molecular weights. Each well received 10 &#956;L of the sample. For
molecular weight estimation, a prestained protein ladder (PageRuler
Plus, 26,619) was used, with 5 &#956;L loaded into the leftmost well
and 10 &#956;L into the rightmost well of the gel. Electrophoresis
was conducted in a NuPAGE MES SDS Running Buffer (NP0002) at 160 V
for approximately 40&#8211;45 min until the desired separation was
achieved.</p><p>Post-electrophoresis, the gels were stained for 1
h using SimplyBlue
SafeStain (LC6060) to visualize the proteins. The gels were subsequently
destained overnight to remove excess stain and enhance the visibility
of the protein bands. Following destaining, the gels were examined
under a UV imager (Amersham Imager 600) to assess the protein separation.</p></sec><sec id="sec2.4"><title>Liquid Chromatography Mass Spectrometry</title><p>Fab protein
samples were prepared at 0.2 mg/mL in water for LC&#8211;MS. An Agilent
6510 QTOF LC&#8211;MS instrument was utilized for analyses. A 10
&#956;L sample was injected through a 100 &#956;L loop onto a reverse
phase RPLC-S, 1000 A, 8 &#956;M, 150 &#215; 2.1 mm column (Part No
PL1912-3802) maintained at 60 &#176;C. The sample tray temperature
was kept at 4 &#176;C. The mobile phases were 0.1% formic acid in
water (A) and 100% acetonitrile in 0.1% formic acid water (B). The
flow rate was 300 &#956;L/min with gradient as follows:- 15% B for
the first 2 min followed by increase to 32% B over 1 min, remained
at 32% B for 1 min. After 4 min of the LC gradient, mobile phase B
was increased to 50% over 10 min, with further increase of B to 95%
over 4 min and maintained at 95% B for 2 min. At 22 min of the LC
gradient, the mobile phase B was changed to 15% B for the next 3 min
to condition the LC column for the next injection. The total LC run
was 25 min. The LC effluent was directed through capillary tubing
into the Agilent 6510 QTOF mass spectrometer with a capillary dual-nebulizer
electrospray ion (ESI) source operating in positive-ion mode, the
parameters were set as follows: Vcapillary voltage 4000 V, fragmentor
voltage 215 V, skimmer voltage 65 V, oct RF Vpp 750 V, oct1 DC 45,
lens1 43.9 V and lens2 32.7 V, amu 500. The ESI source parameters
were nebulizer 20 psi, drying gas temp 325 &#176;C, drying gas flow
5 L/min. The drying gas is nitrogen. The acquisition rate was 1 spectra/sec
and acquisition time 1000 ms/spectrum corresponding to 9652 transients/spectrum.
Data acquisition was performed in profile mode with the mass range
from <italic toggle="yes">m</italic>/<italic toggle="yes">z</italic> 800 to 5000. The data was
processed using maximum entropy deconvolution algorithm incorporated
in MassHunter software (version B.07.00).</p></sec><sec id="sec2.5"><title>Thermal Stability</title><p>Thermal stability assessments were
performed using the UNcle (Unchained Laboratories, UK). Fab samples
were prepared in triplicate at a concentration of 1 mg/mL in a pH
4 solution of 20 mM sodium citrate, 155 mM NaCl (for a total ionic
strength of 200 mM based on theoretical calculations excluding the
Fab). Each sample involved adding 20 &#956;L of 2 mg/mL Fab dissolved
in water to 20 &#956;L of double-concentrated stock buffer. Subsequently,
9 &#956;L from each sample was transferred into a cuvette and loaded
into the UNit for analysis. The samples underwent gradual heating
from 20 to 95 &#176;C, increasing at a linear rate of 1 &#176;C/min,
and monitored by intrinsic fluorescence and static light scattering
(SLS) at 266 and 473 nm. <italic toggle="yes">T</italic>
<sub>agg</sub> measurements
were analyzed using the Uncle software.</p><p>The thermal stability
parameters including the van&#8217;t Hoff enthalpy change (&#916;<italic toggle="yes">H</italic>
<sub>vh</sub>), entropy change (&#916;<italic toggle="yes">S</italic>
<sub>vh</sub>), and the midpoint of thermal unfolding (<italic toggle="yes">T</italic>
<sub>m</sub>)&#58872;where 50% of the protein unfolds&#58872;were
determined using the barycentric mean (BCM) of the intrinsic fluorescence
spectra of the protein across 280&#8211;460 nm wavelengths at ramping
temperature, after fitting to the two-state van&#8217;t Hoff <xref rid="eq1" ref-type="disp-formula">eq <xref rid="eq1" ref-type="disp-formula"/>
</xref>
<disp-formula id="eq1"><label>1</label><alternatives><graphic position="float" orientation="portrait" xlink:href="mp5c00358_m001.jpg"/><mml:math id="d1e341" display="block" overflow="scroll"><mml:msub><mml:mi>I</mml:mi><mml:mi mathvariant="normal">T</mml:mi></mml:msub><mml:mo>=</mml:mo><mml:mfrac><mml:mrow><mml:mrow><mml:mo stretchy="false">(</mml:mo><mml:msub><mml:mi>I</mml:mi><mml:mi mathvariant="normal">N</mml:mi></mml:msub><mml:mo>+</mml:mo><mml:mi>a</mml:mi><mml:mi>T</mml:mi><mml:mo stretchy="false">)</mml:mo></mml:mrow><mml:mo>+</mml:mo><mml:mrow><mml:mo stretchy="false">(</mml:mo><mml:msub><mml:mi>I</mml:mi><mml:mi mathvariant="normal">D</mml:mi></mml:msub><mml:mo>+</mml:mo><mml:mi>b</mml:mi><mml:mi>T</mml:mi><mml:mo stretchy="false">)</mml:mo></mml:mrow><mml:mi>exp</mml:mi><mml:mrow><mml:mo stretchy="true">[</mml:mo><mml:mfrac><mml:mrow><mml:mi mathvariant="normal">&#916;</mml:mi><mml:msub><mml:mi>H</mml:mi><mml:mrow><mml:mi mathvariant="normal">v</mml:mi><mml:mi mathvariant="normal">h</mml:mi></mml:mrow></mml:msub></mml:mrow><mml:mi>R</mml:mi></mml:mfrac><mml:mrow><mml:mo stretchy="true">(</mml:mo><mml:mfrac><mml:mn>1</mml:mn><mml:msub><mml:mi>T</mml:mi><mml:mi mathvariant="normal">m</mml:mi></mml:msub></mml:mfrac><mml:mo>&#8722;</mml:mo><mml:mfrac><mml:mn>1</mml:mn><mml:mi>T</mml:mi></mml:mfrac><mml:mo stretchy="true">)</mml:mo></mml:mrow><mml:mo stretchy="true">]</mml:mo></mml:mrow></mml:mrow><mml:mrow><mml:mn>1</mml:mn><mml:mo>+</mml:mo><mml:mi>exp</mml:mi><mml:mrow><mml:mo stretchy="true">[</mml:mo><mml:mfrac><mml:mrow><mml:mi mathvariant="normal">&#916;</mml:mi><mml:msub><mml:mi>H</mml:mi><mml:mrow><mml:mi mathvariant="normal">v</mml:mi><mml:mi mathvariant="normal">h</mml:mi></mml:mrow></mml:msub></mml:mrow><mml:mi>R</mml:mi></mml:mfrac><mml:mrow><mml:mo stretchy="true">(</mml:mo><mml:mfrac><mml:mn>1</mml:mn><mml:msub><mml:mi>T</mml:mi><mml:mi mathvariant="normal">m</mml:mi></mml:msub></mml:mfrac><mml:mo>&#8722;</mml:mo><mml:mfrac><mml:mn>1</mml:mn><mml:mi>T</mml:mi></mml:mfrac><mml:mo stretchy="true">)</mml:mo></mml:mrow><mml:mo stretchy="true">]</mml:mo></mml:mrow></mml:mrow></mml:mfrac></mml:math></alternatives></disp-formula>
</p><p>Three-state transition <xref rid="eq2" ref-type="disp-formula">eq <xref rid="eq2" ref-type="disp-formula"/>
</xref> was also used to fit the thermal
curves from 221TGA and 222TGA
as a third transition was visible only for these vairants.<disp-formula id="eq2"><label>2</label><alternatives><graphic position="float" orientation="portrait" xlink:href="mp5c00358_m002.jpg"/><mml:math id="d1e453" display="block" overflow="scroll"><mml:msub><mml:mi>I</mml:mi><mml:mi mathvariant="normal">T</mml:mi></mml:msub><mml:mo>=</mml:mo><mml:mfrac><mml:mrow><mml:mrow><mml:mo stretchy="false">(</mml:mo><mml:msub><mml:mi>I</mml:mi><mml:mi mathvariant="normal">N</mml:mi></mml:msub><mml:mo>+</mml:mo><mml:mi>a</mml:mi><mml:mi>T</mml:mi><mml:mo stretchy="false">)</mml:mo></mml:mrow><mml:mo>+</mml:mo><mml:mrow><mml:mo stretchy="false">(</mml:mo><mml:msub><mml:mi>I</mml:mi><mml:mi mathvariant="normal">I</mml:mi></mml:msub><mml:mo>+</mml:mo><mml:mi>b</mml:mi><mml:mi>T</mml:mi><mml:mo stretchy="false">)</mml:mo></mml:mrow><mml:mi>exp</mml:mi><mml:mrow><mml:mo stretchy="true">[</mml:mo><mml:mfrac><mml:mrow><mml:mi mathvariant="normal">&#916;</mml:mi><mml:msub><mml:mi>H</mml:mi><mml:mrow><mml:mrow><mml:mi mathvariant="normal">v</mml:mi><mml:mi mathvariant="normal">h</mml:mi></mml:mrow><mml:mn>1</mml:mn></mml:mrow></mml:msub></mml:mrow><mml:mi>R</mml:mi></mml:mfrac><mml:mrow><mml:mo stretchy="true">(</mml:mo><mml:mfrac><mml:mn>1</mml:mn><mml:msub><mml:mi>T</mml:mi><mml:mrow><mml:mi mathvariant="normal">m</mml:mi><mml:mn>1</mml:mn></mml:mrow></mml:msub></mml:mfrac><mml:mo>&#8722;</mml:mo><mml:mfrac><mml:mn>1</mml:mn><mml:mi>T</mml:mi></mml:mfrac><mml:mo stretchy="true">)</mml:mo></mml:mrow><mml:mo stretchy="true">]</mml:mo></mml:mrow><mml:mo>+</mml:mo><mml:mrow><mml:mo stretchy="false">(</mml:mo><mml:msub><mml:mi>I</mml:mi><mml:mi mathvariant="normal">D</mml:mi></mml:msub><mml:mo>+</mml:mo><mml:mi>c</mml:mi><mml:mi>T</mml:mi><mml:mo stretchy="false">)</mml:mo></mml:mrow><mml:mi>exp</mml:mi><mml:mrow><mml:mo stretchy="true">[</mml:mo><mml:mfrac><mml:mrow><mml:mi mathvariant="normal">&#916;</mml:mi><mml:msub><mml:mi>H</mml:mi><mml:mrow><mml:mrow><mml:mi mathvariant="normal">v</mml:mi><mml:mi mathvariant="normal">h</mml:mi></mml:mrow><mml:mn>1</mml:mn></mml:mrow></mml:msub></mml:mrow><mml:mi>R</mml:mi></mml:mfrac><mml:mrow><mml:mo stretchy="true">(</mml:mo><mml:mfrac><mml:mn>1</mml:mn><mml:msub><mml:mi>T</mml:mi><mml:mrow><mml:mi mathvariant="normal">m</mml:mi><mml:mn>1</mml:mn></mml:mrow></mml:msub></mml:mfrac><mml:mo>&#8722;</mml:mo><mml:mfrac><mml:mn>1</mml:mn><mml:mi>T</mml:mi></mml:mfrac><mml:mo stretchy="true">)</mml:mo></mml:mrow><mml:mo stretchy="true">]</mml:mo></mml:mrow><mml:mi>exp</mml:mi><mml:mrow><mml:mo stretchy="true">[</mml:mo><mml:mfrac><mml:mrow><mml:mi mathvariant="normal">&#916;</mml:mi><mml:msub><mml:mi>H</mml:mi><mml:mrow><mml:mrow><mml:mi mathvariant="normal">v</mml:mi><mml:mi mathvariant="normal">h</mml:mi></mml:mrow><mml:mn>2</mml:mn></mml:mrow></mml:msub></mml:mrow><mml:mi>R</mml:mi></mml:mfrac><mml:mrow><mml:mo stretchy="true">(</mml:mo><mml:mfrac><mml:mn>1</mml:mn><mml:msub><mml:mi>T</mml:mi><mml:mrow><mml:mi mathvariant="normal">m</mml:mi><mml:mn>2</mml:mn></mml:mrow></mml:msub></mml:mfrac><mml:mo>&#8722;</mml:mo><mml:mfrac><mml:mn>1</mml:mn><mml:mi>T</mml:mi></mml:mfrac><mml:mo stretchy="true">)</mml:mo></mml:mrow><mml:mo stretchy="true">]</mml:mo></mml:mrow></mml:mrow><mml:mrow><mml:mn>1</mml:mn><mml:mo>+</mml:mo><mml:mi>exp</mml:mi><mml:mrow><mml:mo stretchy="true">[</mml:mo><mml:mfrac><mml:mrow><mml:mi mathvariant="normal">&#916;</mml:mi><mml:msub><mml:mi>H</mml:mi><mml:mrow><mml:mrow><mml:mi mathvariant="normal">v</mml:mi><mml:mi mathvariant="normal">h</mml:mi></mml:mrow><mml:mn>1</mml:mn></mml:mrow></mml:msub></mml:mrow><mml:mi>R</mml:mi></mml:mfrac><mml:mrow><mml:mo stretchy="true">(</mml:mo><mml:mfrac><mml:mn>1</mml:mn><mml:msub><mml:mi>T</mml:mi><mml:mrow><mml:mi mathvariant="normal">m</mml:mi><mml:mn>1</mml:mn></mml:mrow></mml:msub></mml:mfrac><mml:mo>&#8722;</mml:mo><mml:mfrac><mml:mn>1</mml:mn><mml:mi>T</mml:mi></mml:mfrac><mml:mo stretchy="true">)</mml:mo></mml:mrow><mml:mo stretchy="true">]</mml:mo></mml:mrow><mml:mo>+</mml:mo><mml:mi>exp</mml:mi><mml:mrow><mml:mo stretchy="true">[</mml:mo><mml:mfrac><mml:mrow><mml:mi mathvariant="normal">&#916;</mml:mi><mml:msub><mml:mi>H</mml:mi><mml:mrow><mml:mrow><mml:mi mathvariant="normal">v</mml:mi><mml:mi mathvariant="normal">h</mml:mi></mml:mrow><mml:mn>1</mml:mn></mml:mrow></mml:msub></mml:mrow><mml:mi>R</mml:mi></mml:mfrac><mml:mrow><mml:mo stretchy="true">(</mml:mo><mml:mfrac><mml:mn>1</mml:mn><mml:msub><mml:mi>T</mml:mi><mml:mrow><mml:mi mathvariant="normal">m</mml:mi><mml:mn>1</mml:mn></mml:mrow></mml:msub></mml:mfrac><mml:mo>&#8722;</mml:mo><mml:mfrac><mml:mn>1</mml:mn><mml:mi>T</mml:mi></mml:mfrac><mml:mo stretchy="true">)</mml:mo></mml:mrow><mml:mo stretchy="true">]</mml:mo></mml:mrow><mml:mi>exp</mml:mi><mml:mrow><mml:mo stretchy="true">[</mml:mo><mml:mfrac><mml:mrow><mml:mi mathvariant="normal">&#916;</mml:mi><mml:msub><mml:mi>H</mml:mi><mml:mrow><mml:mrow><mml:mi mathvariant="normal">v</mml:mi><mml:mi mathvariant="normal">h</mml:mi></mml:mrow><mml:mn>2</mml:mn></mml:mrow></mml:msub></mml:mrow><mml:mi>R</mml:mi></mml:mfrac><mml:mrow><mml:mo stretchy="true">(</mml:mo><mml:mfrac><mml:mn>1</mml:mn><mml:msub><mml:mi>T</mml:mi><mml:mrow><mml:mi mathvariant="normal">m</mml:mi><mml:mn>2</mml:mn></mml:mrow></mml:msub></mml:mfrac><mml:mo>&#8722;</mml:mo><mml:mfrac><mml:mn>1</mml:mn><mml:mi>T</mml:mi></mml:mfrac><mml:mo stretchy="true">)</mml:mo></mml:mrow><mml:mo stretchy="true">]</mml:mo></mml:mrow></mml:mrow></mml:mfrac></mml:math></alternatives></disp-formula>where <italic toggle="yes">I</italic>
<sub>N</sub> is the
signal at temperature <italic toggle="yes">T</italic>, <italic toggle="yes">I</italic>
<sub>N</sub>, <italic toggle="yes">I</italic>
<sub>D</sub>, and <italic toggle="yes">I</italic>
<sub>I</sub> are the signals of the native, denatured and intermediate states, <italic toggle="yes">a</italic>, <italic toggle="yes">b</italic> are the native and denatured region
baseline slopes, and <italic toggle="yes">R</italic> is the molar gas constant.</p></sec><sec id="sec2.6"><title>Aggregation Kinetics</title><p>A double-concentrated stock buffer
was prepared as described for the thermal stability assessments and
combined with 2 mg/mL of Fab in Milli-Q water to attain a final concentration
of 1 mg/mL in 20 mM sodium citrate pH 4, 155 mM NaCl. Each sample,
measuring 20 &#956;L, was dispensed into a 0.2 mL thin-walled RNase-free
PCR tube (Fisher Scientific, UK) and placed in a thermal cycler (Bio-Rad
C1000 Touch, UK) preset at 4 &#176;C. Isothermal program of 65 &#176;C
was initiated and samples were taken in triplicate for each variant
at intervals of 5 min, immediately cooled on ice for 5 min, and then
centrifuged at 21,300<italic toggle="yes">g</italic> at 4 &#176;C for 15 min. From
the resultant supernatant, 15 &#956;L was transferred to an HPLC
vial insert and 5 &#956;L was injected into an Agilent Diol Guard
Column (4.6 mm ID &#215; 12.5 mm), followed by an Agilent Zorbax Bio
Series GF-250 SEC-HPLC column (Agilent, Berkshire, UK). The SEC-HPLC
operated at a flow rate of 1 mL/min using 200 mM sodium phosphate
buffer at pH 7 on an Agilent 1200 HPLC system (Cheshire, UK), running
each cycle for 4.5 min. Calibration curves were established with injections
of 0, 1, 2, and 5 &#956;L from a 2 mg/mL solution prior to each batch
of analysis.</p><p>To model the kinetics of monomer loss, an exponential
function (<xref rid="eq3" ref-type="disp-formula">eq <xref rid="eq3" ref-type="disp-formula"/>
</xref>) was used
where <italic toggle="yes">A</italic> and <italic toggle="yes">k</italic> are the coefficients, <italic toggle="yes">y</italic> represents the normalized monomer retention from 0 to
1, and <italic toggle="yes">t</italic> denotes the incubation time. The initial
rate of aggregation <italic toggle="yes">v</italic> at <italic toggle="yes">t</italic> = 0 is
given by the first derivative of <xref rid="eq3" ref-type="disp-formula">eq <xref rid="eq3" ref-type="disp-formula"/>
</xref>, which is <italic toggle="yes">A</italic> &#215; <italic toggle="yes">k</italic> in min<sup>&#8211;1</sup>.<disp-formula id="eq3"><label>3</label><alternatives><graphic position="float" orientation="portrait" xlink:href="mp5c00358_m003.jpg"/><mml:math id="d1e805" display="block" overflow="scroll"><mml:mi>y</mml:mi><mml:mo>=</mml:mo><mml:mi>A</mml:mi><mml:mo>&#215;</mml:mo><mml:msup><mml:mi mathvariant="normal">e</mml:mi><mml:mrow><mml:mo stretchy="false">(</mml:mo><mml:mo form="prefix">&#8722;</mml:mo><mml:mi>k</mml:mi><mml:mi>t</mml:mi><mml:mo stretchy="false">)</mml:mo></mml:mrow></mml:msup></mml:math></alternatives></disp-formula>
</p></sec></sec><sec id="sec3"><title>Results and Discussion</title><sec id="sec3.1"><title>Assessment of Monomeric and Dimeric States
of Fab Variants by
SDS-PAGE, SEC-HPLC and Mass Spectrometry</title><p>Having successfully
introduced the stop codons in the Fab variants, as confirmed by sequencing,
it was imperative to assess the hinge truncation and overall integrity
of the expressed and purified Fab variants prior to performing any
forced degradation studies of aggregation. These evaluations were
necessary due to the potential instability and formation of atypical
oligomers in the new variants. As depicted in <xref rid="fig2" ref-type="fig">Figure <xref rid="fig2" ref-type="fig"/>
</xref>, SDS-PAGE analysis was performed under both
non-reducing and reducing conditions to evaluate the molecular integrity
and homogeneity of the protein variants.</p><fig position="float" id="fig2" fig-type="figure" orientation="portrait"><label>2</label><caption><p>Comparative SDS-PAGE
analysis under nonreducing (A) and reducing
(B) conditions. Protein ladders are loaded in the outermost lanes
of both gels. Eight Fab variants of 221TGA to 228TGA along with the
wild type samples are loaded in the center wells, progressing from
left to right.</p></caption><graphic id="gr2" position="float" orientation="portrait" xlink:href="mp5c00358_0002.jpg"/></fig><p>Under non-reducing conditions,
the predominant
bands for all samples
were observed just below 55 kDa, accompanied by minor bands just below
25 kDa. These bands corresponded to the full Fab fragments (approximately
47 kDa) and the light chain/heavy chain (LC/HC) fragments (approximately
23&#8211;24 kDa), respectively. The molecular weight differences
resulting from the progressive truncations of 1&#8211;8 residues
between the variants were not surprisingly indiscernible due to the
resolution limitations of SDS-PAGE.</p><p>All variants showed a band
at between 130 and 250 kDa, indicative
of higher molecular weight species. This band was most intense for
the 221TGA variant and less so for 222TGA, but then much fainter for
the remaining variants 223TGA to 228TGA, and absent for wild type.
The presence of this band is well beyond the expected molecular weight
of a Fab&#8211;Fab dimer (93 kDa), suggesting the formation of a
higher order Fab oligomer, such as a trimer (140 kDa) or tetramer
(186 kDa). A weak band at around 70 kDa was exclusively observed in
the 221TGA variant, suggesting unique oligomerization patterns possibly
due to mis-paired cysteine residues leading to dimerization between
Fab fragments and LC/HC, forming Fab-LC (70.0 kDa) and Fab-HC (69.7
kDa) species in the 221TGA variant, or possibly due to the formation
of a disulfide bond with a host cell protein.</p><p>Under reducing
conditions, the major band was consistently observed
at slightly below 25 kDa across all variants, indicating the presence
of the LC and HC fragments. For the 221TGA variant, two additional
bands in the range of 55&#8211;60 kDa were detected, with a reduced
intensity observed in the 222TGA variant, and progressively fainter
in variants 223TGA to 228TGA and wild type. The origin of these bands
remains unclear but may be attributed to proteolytic cleavage of Fab-LC
or Fab-HC, which exhibit molecular weights of 69&#8211;70 kDa, or
again due to a &#8764;50 kDa host cell protein co-purified due to
formation of a disulfide bond with the Fab.</p><p>SEC-HPLC was utilized
to further evaluate the monomer homogeneity
and potential oligomerization of the Fab variants as illustrated in <xref rid="fig3" ref-type="fig">Figure <xref rid="fig3" ref-type="fig"/>
</xref>, supplementing the
SDS-PAGE findings. A predominant monomer peak was consistently observed
at approximately 2.7 min across all variants, indicating the primary
presence of monomeric Fab. An additional peak was detected around
2.2&#8211;2.3 min for all variants but not wild type. The height
of this peak increased progressively along the truncation series from
very small (&lt;0.2 mAU above baseline) for 228TGA to slightly larger
(0.5 mAU above baseline) for 223TGA, but then increased notably to
1.2 mAU above baseline for 222TGA and then 8 mAU above baseline for
the 221TGA variant. While the presence of larger oligomers was expected
to be excluded by the guard column, this earlier eluting peak suggests
the presence of small, soluble oligomers, likely resulting from mis-paired
cysteines. The molecular composition of these oligomers may include
Fab trimers/tetramers, as previously indicated in the SDS-PAGE analysis,
possibly in conjunction with Fab dimers and mixed Fab-LC/HC species.</p><fig position="float" id="fig3" fig-type="figure" orientation="portrait"><label>3</label><caption><p>HPLC size
exclusion chromatograms of the wild type (WT) and eight
hinge-truncated variants from calibration. Samples were prepared at
a concentration of 2 mg/mL, with injection volumes of 2 &#956;L.
Each variant is distinguished by a different color. The dimer species
predominantly elutes at approximately 2.2&#8211;2.3 min, whereas
the monomer elutes at around 2.7 min. Panel (B) provides a zoomed-in
view of Panel (A) focusing on the elution time between 2.0 and 2.6
min.</p></caption><graphic id="gr3" position="float" orientation="portrait" xlink:href="mp5c00358_0003.jpg"/></fig><p>Liquid chromatography&#8211;mass
spectrometry
(LC&#8211;MS) analysis
was used to further elucidate the oligomerization states of the eight
protein variants alongside the wild type, as shown in <xref rid="fig4" ref-type="fig">Figure <xref rid="fig4" ref-type="fig"/>
</xref>. Consistently, a principal
peak at approximately 46&#8211;47 kDa was observed for the wild type
and all variants, confirming the predominance of the monomeric forms
and indicating their good homogeneity. No other significant peaks
were observed for wild type, or for the variants 222TGA to 228TGA.
However, the variant 221TGA exhibited an additional peak at approximately
146 kDa, a mass coinciding nearly with the expected 140 kDa of its
trimeric form and distinctly below the tetrameric form (186 kDa).
The same peak was only very weakly observable above the noise for
222TGA, but not for the other variants. This suggests that the larger
molecular species observed in the SDS-PAGE and SEC-HPLC analyses likely
corresponded also predominantly to Fab trimers, with potential contributions
from other heterogeneously sized oligomers such as dimers or antibody
light chain-heavy chain (Fab-LC/HC) complexes. A comprehensive spectroscopic
characterization of these findings is presented in the <ext-link xlink:href="https://pubs.acs.org/doi/suppl/10.1021/acs.molpharmaceut.5c00358/suppl_file/mp5c00358_si_001.pdf" ext-link-type="uri">Supporting Information</ext-link>.</p><fig position="float" id="fig4" fig-type="figure" orientation="portrait"><label>4</label><caption><p>Mass spectroscopy analysis
of the variants 221TGA (A), 222TGA (B)
and wild type (C). Background signals were subtracted prior to deconvolution
of the data. The complete data set for all the variants can be found
in the <ext-link xlink:href="https://pubs.acs.org/doi/suppl/10.1021/acs.molpharmaceut.5c00358/suppl_file/mp5c00358_si_001.pdf" ext-link-type="uri">Supporting Information</ext-link>.</p></caption><graphic id="gr4" position="float" orientation="portrait" xlink:href="mp5c00358_0004.jpg"/></fig></sec><sec id="sec3.2"><title>Thermal Stability Analysis</title><p>The thermal stability of
the Fab variants was assessed from changes in the barycentric mean
(BCM) of intrinsic fluorescence spectra as the temperature was increased.
The Fab molecules were formulated in 20 mM sodium citrate, pH 4, 155
mM NaCl (200 mM total ionic strength) to ensure consistency with previous
aggregation studies of the same Fab.<xref rid="ref23" ref-type="bibr"/> For
the majority of the samples, thermal transitions were adequately described
by van&#8217;t Hoff two-state models (<xref rid="eq1" ref-type="disp-formula">eq <xref rid="eq1" ref-type="disp-formula"/>
</xref>). However, for the variants 221TGA and 222TGA,
a more complex three-state model was necessary (<xref rid="eq2" ref-type="disp-formula">eq <xref rid="eq2" ref-type="disp-formula"/>
</xref>), presumably resulting from denaturation
of the oligomeric states identified by the SDS-PAGE, SEC and LC&#8211;MS
analyses above.</p><p>Specifically, the BCM data for 221TGA showed
two distinct melting temperatures (<italic toggle="yes">T</italic>
<sub>m1</sub> and <italic toggle="yes">T</italic>
<sub>m2</sub>) which were accurately modeled
(residual sum of squares = 0.40) by the three-state model in one of
the triplicate measurements (<xref rid="fig5" ref-type="fig">Figure <xref rid="fig5" ref-type="fig"/>
</xref>C), suggesting a well-fitted model, but overfitted
the weaker second transition in the other two replicas (<xref rid="fig5" ref-type="fig">Figure <xref rid="fig5" ref-type="fig"/>
</xref>A,B). For 222TGA, the three-state
model overfitted for replica 1, fitted poorly for replica 2 (residual
sum of squares = 7.6), but fitted well for replica 3 (residual sum
of squares = 1.0) (<xref rid="fig5" ref-type="fig">Figure <xref rid="fig5" ref-type="fig"/>
</xref>D&#8211;F). By contrast, the two-state model gave a single <italic toggle="yes">T</italic>
<sub>m</sub> value centered on the first transition, though
with an uncertain upper baseline fit. For both 221TGA and 222TGA,
we retained the data from both fitting methods for comparison to other
variants as their fitting statistics (residual sum of squares = 0.7&#8211;2.5)
were still improved compared to the three-state fits. Detailed BCM
spectral data and associated fitting statistics for all Fab variant
replicas are provided in the <ext-link xlink:href="https://pubs.acs.org/doi/suppl/10.1021/acs.molpharmaceut.5c00358/suppl_file/mp5c00358_si_001.pdf" ext-link-type="uri">Supporting Information</ext-link>.</p><fig position="float" id="fig5" fig-type="figure" orientation="portrait"><label>5</label><caption><p>Barycentric mean (BCM) of intrinsic fluorescence spectra across
temperature gradients for variants 221TGA (A&amp;C) and 222TGA (B&amp;D),
fitted to van&#8217;t Hoff thermal transitions. The black squares
represent actual measurements while the red lines indicate model fittings
using two-state (top, A,B) and three-state (bottom, C,D) equations.
The transition temperatures are marked with arrows. Comments on the
fitting quality are included to assess the adequacy of the model fit
for each scenario.</p></caption><graphic id="gr5" position="float" orientation="portrait" xlink:href="mp5c00358_0005.jpg"/></fig><p>
<xref rid="fig6" ref-type="fig">Figure <xref rid="fig6" ref-type="fig"/>
</xref> presents
the melting temperatures (<italic toggle="yes">T</italic>
<sub>m</sub>) and corresponding
van&#8217;t Hoff entropy changes (&#916;<italic toggle="yes">S</italic>
<sub>vh</sub>), calculated using the two-state model for all variants, in addition
to the three-state model for only 221TGA and 222TGA. The <italic toggle="yes">T</italic>
<sub>m</sub> values for most variants closely approximated that of
the wild type, ranging from 69.0 to 70.5 &#176;C. Notably, variants
221TGA and 222TGA exhibited slightly lower <italic toggle="yes">T</italic>
<sub>m</sub> values for the two-state model, between 66.8 and 67.6 &#176;C,
likely as a result of part of the signal change resolving out to give
a separate second transition at high temperature. The <italic toggle="yes">T</italic>
<sub>m</sub> values from the three-state model for these particular
variants were 68.1 and 82.8 &#176;C for 221TGA, and 72.3 and 77.3
&#176;C for 222TGA.</p><fig position="float" id="fig6" fig-type="figure" orientation="portrait"><label>6</label><caption><p>Melting temperature (<italic toggle="yes">T</italic>
<sub>m</sub>, orange
bars)
and van&#8217;t Hoff entropy change (&#916;<italic toggle="yes">S</italic>
<sub>vh</sub>, green bars) for the Fab wild type (WT) and its variants
labeled as 221TGA to 228TGA, fitted with a two-state thermal transition
equation. For the 221TGA and 222TGA variants, values from a three-state
fit are included. Dashed reference lines indicate the baseline values
for WT, facilitating direct comparison of each variant&#8217;s stability
relative to the WT.</p></caption><graphic id="gr6" position="float" orientation="portrait" xlink:href="mp5c00358_0006.jpg"/></fig><p>&#916;<italic toggle="yes">S</italic>
<sub>vh</sub> values can
be used to monitor
conformational flexibility, with elevated values suggesting a decrease
in conformational flexibility within the native state, potentially
leading to diminished aggregation tendencies by reducing the population
of near-native, aggregation-prone conformers. Significant variations
in &#916;<italic toggle="yes">S</italic>
<sub>vh</sub> were observed among the
variants. Notably, the variants 226TGA, 227TGA, and 228TGA exhibited
increases of 12&#8211;20% compared to wild type. Variants 221TGA
and 222TGA showed much larger (63&#8211;68%) increases in &#916;<italic toggle="yes">S</italic>
<sub>vh</sub> compared to wild type based on two-state
fitting. This reflects an apparently decreased conformational flexibility
although this is also affected by the emergence of a second transition.
The three-state fitting led to much lower values when comparing only
their first transitions, but it is not really possible to compare
these directly to the simpler two-state transitions observed for the
wild type and other variants.</p><p>Static light scattering (SLS)
measurements were conducted to rapidly
assess the aggregation of various Fab variants. The SLS profiles at
both 266 and 473 nm show that variants 221TGA and 222TGA experienced
a pronounced increase in scattering intensity at lower temperatures
compared to other variants (<xref rid="fig7" ref-type="fig">Figure <xref rid="fig7" ref-type="fig"/>
</xref>A,B), indicating potential instability associated with
the exposure of the LC214-HC220 disulfide bond. Conversely, variants
225TGA through 228TGA exhibited relatively higher temperatures prior
to increases in SLS-266 nm signals, suggesting more favorable aggregation
kinetics. Variants 223TGA and 224TGA, however, showed slightly earlier
increases in their scattering intensity (<xref rid="fig7" ref-type="fig">Figure <xref rid="fig7" ref-type="fig"/>
</xref>A).</p><fig position="float" id="fig7" fig-type="figure" orientation="portrait"><label>7</label><caption><p>Static light scattering analysis of Fab variants.
Panels (A) and
(B) display the static light scattering (SLS) intensity profiles for
the Fab wild type (WT) and its variants at 266 and 473 nm wavelengths,
respectively. Each variant is represented by a distinct color with
three repeat measurements in the same color. The corresponding aggregation
onset temperatures (<italic toggle="yes">T</italic>
<sub>agg</sub>) are summarized
in panel (C), indicating <italic toggle="yes">T</italic>
<sub>agg</sub> values at
266 nm (orange bars) and 473 nm (green bars), with standard error
of the mean (SEM) represented by error bars for each data point. Dashed
reference lines indicate the baseline values for WT, facilitating
direct comparison of each variant&#8217;s stability relative to the
WT.</p></caption><graphic id="gr7" position="float" orientation="portrait" xlink:href="mp5c00358_0007.jpg"/></fig><p>The SLS data at 473 nm indicated
that the 221TGA
and 222TGA variants
began to form larger particles at lower temperatures, with a marked
increase in scattering intensity after 70 &#176;C. In contrast, the
remaining variants initiated particle formation at slightly higher
temperatures of 80 &#176;C, and demonstrated lower scattering intensity.
The differentiation among the variants based on scattering intensity
at 473 nm was minimal, likely due to the reduced sensitivity of this
wavelength to smaller aggregate forms (<xref rid="fig7" ref-type="fig">Figure <xref rid="fig7" ref-type="fig"/>
</xref>B). Moreover, the <italic toggle="yes">T</italic>
<sub>agg</sub> values derived from the Uncle software (<xref rid="fig7" ref-type="fig">Figure <xref rid="fig7" ref-type="fig"/>
</xref>C) did not always reflect the
stability ranking observable directly from the SLS spectra profiles.
These values primarily capture the point at which scattering intensity
increased, which was relatively similar across the variants other
than for 221TGA.</p></sec><sec id="sec3.3"><title>Aggregation Kinetics of Hinge-Truncated Variants
of Fab Analyzed
by SEC-HPLC</title><p>The aggregation kinetics of WT Fab and the hinge-truncated
variants were quantitatively analyzed by monomer retention using SEC-HPLC
over time as shown in <xref rid="fig8" ref-type="fig">Figure <xref rid="fig8" ref-type="fig"/>
</xref>A. Measurements for triplicate samples are shown alongside
their curves fitted independently to <xref rid="eq3" ref-type="disp-formula">eq <xref rid="eq3" ref-type="disp-formula"/>
</xref>. The aggregation kinetic constants for these variants
and WT are shown in <xref rid="fig8" ref-type="fig">Figure <xref rid="fig8" ref-type="fig"/>
</xref>B. <xref rid="tbl1" ref-type="table">Table <xref rid="tbl1" ref-type="table"/>
</xref> summarizes
the kinetic parameters and thermal stability data.</p><fig position="float" id="fig8" fig-type="figure" orientation="portrait"><label>8</label><caption><p>Aggregation kinetics
as measured by SEC-HPLC. Panel (A) the monomer
retention over time for the wild type (WT) and eight hinge-truncated
variants. All three replicas are shown for each variant at each time-point.
For each variant, a single monomer retention curve is fitted to the
combined replica data (24 data points) using <xref rid="eq3" ref-type="disp-formula">eq <xref rid="eq3" ref-type="disp-formula"/>
</xref> to derive the kinetic constant, <italic toggle="yes">k</italic>, modeled reaction coefficient, <italic toggle="yes">A</italic>, and associated
standard fitting errors. Unique colors and symbols represent each
variant. Panel (B) aggregation rate constant <italic toggle="yes">k</italic> and
initial aggregation rate derived from <xref rid="eq3" ref-type="disp-formula">eq <xref rid="eq3" ref-type="disp-formula"/>
</xref> and <italic toggle="yes">A</italic> &#215; <italic toggle="yes">k</italic> respectively.
Reference lines for WT are included for comparison. Error bars represent
standard errors based on parameter fitting errors.</p></caption><graphic id="gr8" position="float" orientation="portrait" xlink:href="mp5c00358_0008.jpg"/></fig><table-wrap position="float" id="tbl1" orientation="portrait"><label>1</label><caption><title>Data Summary of Thermal Stability
and Aggregation Kinetics for the Fab Wild Type and Variants<xref rid="t1fn1" ref-type="table-fn"/>
</title></caption><table frame="hsides" rules="groups"><colgroup span="1"><col align="left" span="1"/><col align="char" char="." span="1"/><col align="char" char="." span="1"/><col align="char" char="." span="1"/><col align="char" char="." span="1"/><col align="char" char="." span="1"/><col align="char" char="." span="1"/><col align="char" char="." span="1"/><col align="char" char="." span="1"/><col align="char" char="." span="1"/><col align="char" char="." span="1"/><col align="char" char="." span="1"/></colgroup><thead><tr><th align="center" colspan="1" rowspan="1">&#160;</th><th colspan="2" align="center" char="." rowspan="1">
<italic toggle="yes">T</italic>
<sub>m</sub> (&#176;C)<hr/></th><th colspan="2" align="center" char="." rowspan="1">&#916;<italic toggle="yes">H</italic>
<sub>vh</sub> (kJ/mol)<hr/></th><th colspan="2" align="center" char="." rowspan="1">&#916;<italic toggle="yes">S</italic>
<sub>vh</sub> (kJ/mol&#160;K)<hr/></th><th colspan="2" align="center" char="." rowspan="1">aggregation
rate constant<hr/></th><th align="center" char="." colspan="1" rowspan="1">modelled coefficient&#160;<italic toggle="yes">A</italic>
<hr/></th><th colspan="2" align="center" char="." rowspan="1">initial
aggregation rate<hr/></th></tr><tr><th align="center" colspan="1" rowspan="1">variant ID</th><th align="center" char="." colspan="1" rowspan="1">Ave</th><th align="center" char="." colspan="1" rowspan="1">SEM</th><th align="center" char="." colspan="1" rowspan="1">Ave</th><th align="center" char="." colspan="1" rowspan="1">SEM</th><th align="center" char="." colspan="1" rowspan="1">Ave</th><th align="center" char="." colspan="1" rowspan="1">SEM</th><th align="center" char="." colspan="1" rowspan="1">
<italic toggle="yes">k</italic> (min<sup>&#8211;1</sup>)</th><th align="center" char="." colspan="1" rowspan="1">SE</th><th align="center" char="." colspan="1" rowspan="1">&#160;</th><th align="center" char="." colspan="1" rowspan="1">rate (min<sup>&#8211;1</sup>)</th><th align="center" char="." colspan="1" rowspan="1">relative to WT</th></tr></thead><tbody><tr><td align="left" colspan="1" rowspan="1">221TGA</td><td align="char" char="." colspan="1" rowspan="1">66.8</td><td align="char" char="." colspan="1" rowspan="1">0.13</td><td align="char" char="." colspan="1" rowspan="1">653</td><td align="char" char="." colspan="1" rowspan="1">74</td><td align="char" char="." colspan="1" rowspan="1">1.9</td><td align="char" char="." colspan="1" rowspan="1">0.22</td><td align="char" char="." colspan="1" rowspan="1">0.0349</td><td align="char" char="." colspan="1" rowspan="1">0.0005</td><td align="char" char="." colspan="1" rowspan="1">0.986</td><td align="char" char="." colspan="1" rowspan="1">0.0344</td><td align="char" char="." colspan="1" rowspan="1">&#8211;13.0%</td></tr><tr><td align="left" colspan="1" rowspan="1">222TGA</td><td align="char" char="." colspan="1" rowspan="1">67.6</td><td align="char" char="." colspan="1" rowspan="1">0.11</td><td align="char" char="." colspan="1" rowspan="1">677</td><td align="char" char="." colspan="1" rowspan="1">18</td><td align="char" char="." colspan="1" rowspan="1">2.0</td><td align="char" char="." colspan="1" rowspan="1">0.05</td><td align="char" char="." colspan="1" rowspan="1">0.038</td><td align="char" char="." colspan="1" rowspan="1">0.001</td><td align="char" char="." colspan="1" rowspan="1">0.987</td><td align="char" char="." colspan="1" rowspan="1">0.0376</td><td align="char" char="." colspan="1" rowspan="1">&#8211;5.2%</td></tr><tr><td align="left" colspan="1" rowspan="1">223TGA</td><td align="char" char="." colspan="1" rowspan="1">70.2</td><td align="char" char="." colspan="1" rowspan="1">0.15</td><td align="char" char="." colspan="1" rowspan="1">407</td><td align="char" char="." colspan="1" rowspan="1">22</td><td align="char" char="." colspan="1" rowspan="1">1.2</td><td align="char" char="." colspan="1" rowspan="1">0.06</td><td align="char" char="." colspan="1" rowspan="1">0.039</td><td align="char" char="." colspan="1" rowspan="1">0.001</td><td align="char" char="." colspan="1" rowspan="1">0.973</td><td align="char" char="." colspan="1" rowspan="1">0.0378</td><td align="char" char="." colspan="1" rowspan="1">&#8211;4.6%</td></tr><tr><td align="left" colspan="1" rowspan="1">224TGA</td><td align="char" char="." colspan="1" rowspan="1">70.5</td><td align="char" char="." colspan="1" rowspan="1">0.09</td><td align="char" char="." colspan="1" rowspan="1">376</td><td align="char" char="." colspan="1" rowspan="1">12</td><td align="char" char="." colspan="1" rowspan="1">1.1</td><td align="char" char="." colspan="1" rowspan="1">0.03</td><td align="char" char="." colspan="1" rowspan="1">0.040</td><td align="char" char="." colspan="1" rowspan="1">0.001</td><td align="char" char="." colspan="1" rowspan="1">0.969</td><td align="char" char="." colspan="1" rowspan="1">0.0389</td><td align="char" char="." colspan="1" rowspan="1">&#8211;1.7%</td></tr><tr><td align="left" colspan="1" rowspan="1">225TGA</td><td align="char" char="." colspan="1" rowspan="1">69.7</td><td align="char" char="." colspan="1" rowspan="1">0.09</td><td align="char" char="." colspan="1" rowspan="1">411</td><td align="char" char="." colspan="1" rowspan="1">22</td><td align="char" char="." colspan="1" rowspan="1">1.2</td><td align="char" char="." colspan="1" rowspan="1">0.06</td><td align="char" char="." colspan="1" rowspan="1">0.0399</td><td align="char" char="." colspan="1" rowspan="1">0.0014</td><td align="char" char="." colspan="1" rowspan="1">0.943</td><td align="char" char="." colspan="1" rowspan="1">0.0377</td><td align="char" char="." colspan="1" rowspan="1">&#8211;4.9%</td></tr><tr><td align="left" colspan="1" rowspan="1">226TGA</td><td align="char" char="." colspan="1" rowspan="1">69.5</td><td align="char" char="." colspan="1" rowspan="1">0.1</td><td align="char" char="." colspan="1" rowspan="1">452</td><td align="char" char="." colspan="1" rowspan="1">15</td><td align="char" char="." colspan="1" rowspan="1">1.3</td><td align="char" char="." colspan="1" rowspan="1">0.04</td><td align="char" char="." colspan="1" rowspan="1">0.0384</td><td align="char" char="." colspan="1" rowspan="1">0.0016</td><td align="char" char="." colspan="1" rowspan="1">0.952</td><td align="char" char="." colspan="1" rowspan="1">0.0366</td><td align="char" char="." colspan="1" rowspan="1">&#8211;7.6%</td></tr><tr><td align="left" colspan="1" rowspan="1">227TGA</td><td align="char" char="." colspan="1" rowspan="1">69.6</td><td align="char" char="." colspan="1" rowspan="1">0.08</td><td align="char" char="." colspan="1" rowspan="1">486</td><td align="char" char="." colspan="1" rowspan="1">4</td><td align="char" char="." colspan="1" rowspan="1">1.4</td><td align="char" char="." colspan="1" rowspan="1">0.01</td><td align="char" char="." colspan="1" rowspan="1">0.0347</td><td align="char" char="." colspan="1" rowspan="1">0.0007</td><td align="char" char="." colspan="1" rowspan="1">0.975</td><td align="char" char="." colspan="1" rowspan="1">0.0338</td><td align="char" char="." colspan="1" rowspan="1">&#8211;14.5%</td></tr><tr><td align="left" colspan="1" rowspan="1">228TGA</td><td align="char" char="." colspan="1" rowspan="1">70.0</td><td align="char" char="." colspan="1" rowspan="1">0.16</td><td align="char" char="." colspan="1" rowspan="1">455</td><td align="char" char="." colspan="1" rowspan="1">9</td><td align="char" char="." colspan="1" rowspan="1">1.3</td><td align="char" char="." colspan="1" rowspan="1">0.03</td><td align="char" char="." colspan="1" rowspan="1">0.0363</td><td align="char" char="." colspan="1" rowspan="1">0.0006</td><td align="char" char="." colspan="1" rowspan="1">0.981</td><td align="char" char="." colspan="1" rowspan="1">0.0356</td><td align="char" char="." colspan="1" rowspan="1">&#8211;10.0%</td></tr><tr><td align="left" colspan="1" rowspan="1">WT</td><td align="char" char="." colspan="1" rowspan="1">69.0</td><td align="char" char="." colspan="1" rowspan="1">0.24</td><td align="char" char="." colspan="1" rowspan="1">404</td><td align="char" char="." colspan="1" rowspan="1">24</td><td align="char" char="." colspan="1" rowspan="1">1.2</td><td align="char" char="." colspan="1" rowspan="1">0.07</td><td align="char" char="." colspan="1" rowspan="1">0.0406</td><td align="char" char="." colspan="1" rowspan="1">0.0007</td><td align="char" char="." colspan="1" rowspan="1">0.976</td><td align="char" char="." colspan="1" rowspan="1">0.0396</td><td align="char" char="." colspan="1" rowspan="1">0.0%</td></tr></tbody></table><table-wrap-foot><fn id="t1fn1"><label>a</label><p>The melting temperature (<italic toggle="yes">T</italic>
<sub>m</sub>), enthalpy
change of unfolding (&#916;<italic toggle="yes">H</italic>
<sub>vh</sub>), and
entropy change of unfolding (&#916;<italic toggle="yes">S</italic>
<sub>vh</sub>) for individual repeats were determined by
fitting barycentric mean (BCM) intrinsic fluorescence spectra to a
two-state transition model. Averaged (Ave) and standard errors of
the mean (SEM) were from triplicate measurements. Aggregation kinetics
were analysed by fitting the combined monomer retention data for triplicates
to <xref rid="eq3" ref-type="disp-formula">eq <xref rid="eq3" ref-type="disp-formula"/>
</xref> to determine
the rate constant <italic toggle="yes">k</italic> and modelled coefficient A for
each variant, and associated standard error (SE) from fitting.</p></fn></table-wrap-foot></table-wrap><p>Generally, all variants followed
first-order kinetics,
exhibiting
lower aggregation rates than WT. Notably, the shortest hinge variant,
221TGA, showed a 13.0% reduction in aggregation rate. As the hinge
length increased stepwise for the next four residues, the aggregation
rate approached that of WT, with 224TGA showing a minimal reduction
of 1.7%. Further extension of the hinge length resulted in a continued
decrease in aggregation rate, with 227TGA and 228TGA displaying reductions
of 14.5% and 10.0%, respectively.</p><p>The overall kinetics of aggregation
were maximally decreased by
14.5%, highlighting the effectiveness of optimizing hinge length as
a strategy to mitigate aggregation. A correlation between aggregation
rate and the van&#8217;t Hoff entropy change (&#916;<italic toggle="yes">S</italic>
<sub>vh</sub>), in <xref rid="fig9" ref-type="fig">Figure <xref rid="fig9" ref-type="fig"/>
</xref>, demonstrates a strong linear relationship (<italic toggle="yes">R</italic>
<sup>2</sup> = 0.936) when excluding the outlier variants 221TGA
and 222TGA that had two thermal melting transitions instead of one.
Thus, reduction in the overall native protein flexibility led to slower
aggregation. This result, in which aggregation kinetics correlated
with &#916;<italic toggle="yes">S</italic>
<sub>vh</sub> while the <italic toggle="yes">T</italic>
<sub>m</sub> values remained unchanged was also observed in our previous
work in which stabilizing mutations were targeted to regions with
the most flexible structure in the C<sub>H</sub> and C<sub>L</sub> domains.<named-content content-type="bibref-group">
<xref rid="ref26" ref-type="bibr"/>,<xref rid="ref27" ref-type="bibr"/>
</named-content> Thus, as proposed in that work,
it is likely that flexibility in the hinge region and surrounding
structure plays a role in promoting aggregation of A33Fab, potentially
through partial unfolding to increase solvent exposure of an aggregation
prone region. Stabilizing mutations, or the hinge truncations of the
present study, can be used to minimize flexibility and partial unfolding
of local regions that therefore minimize aggregation.</p><fig position="float" id="fig9" fig-type="figure" orientation="portrait"><label>9</label><caption><p>Linear regression analysis
of the initial aggregation rate versus
van&#8217;t Hoff entropy change (&#916;<italic toggle="yes">S</italic>
<sub>vh</sub>) for various Fab variants. The red line represents the linear fit,
excluding outliers 221TGA and 222TGA.</p></caption><graphic id="gr9" position="float" orientation="portrait" xlink:href="mp5c00358_0009.jpg"/></fig><p>The increased &#916;<italic toggle="yes">S</italic>
<sub>vh</sub> in the outliers
221TGA and 222TGA was likely to have been linked to the observed increase
in oligomerization within the starting material, resulting from disulfide
bond formation between the exposed cysteine residues. This would complicate
their aggregation behavior by involving both covalent oligomer formation
and noncovalent monomer aggregation, which skews their data from the
linear trend. The impact of aggregates on unfolding cooperativity,
measured as &#916;<italic toggle="yes">S</italic>
<sub>vh</sub> (or &#916;<italic toggle="yes">H</italic>
<sub>vh</sub>), is well-known.<xref rid="ref28" ref-type="bibr"/>
</p><p>Despite the increased presence of oligomers in the 221TGA
and 222TGA
starting materials, these variants showed significant reductions in
aggregation rate. This indicates that the subsequent aggregation of
Fab monomers under the forced degradation conditions was independent
of the initial oligomer formation. Regardless, the instability of
exposed cysteine residues, particularly in 221TGA, could lead to posttranslational
modifications, complicating downstream purification processes and
posing regulatory challenges. Conversely, variants 227TGA and 228TGA
demonstrated optimal characteristics for reducing aggregation with
no initial oligomer formation. Notably, the 14.5% reduction in aggregation
observed with 227TGA represents an enhancement over the previous mutational
optimization, which achieved improvements in the range of 5&#8211;11%.<xref rid="ref26" ref-type="bibr"/>
</p><p>Overall, the most extensive truncation
of the A33 Fab hinge in
221TGA, and less so for 222TGA, led to more oligomers in the initially
purified protein as detected by SDS-PAGE, SEC and LC&#8211;MS, and
also indirectly through SLS. Oxidising versus reducing SDS-PAGE indicated
that these were formed through intermolecular disulfide bonds, most
likely as a result of greater solvent exposure of the cysteines at
residues LC-214 and HC-220. The initial presence of these oligomers
did not appear to directly influence subsequent aggregation kinetics
in the forced degradation conditions, but they did alter the unfolding
cooperativity of the 221TGA and 222TGA variants as evidenced by their
increased &#916;<italic toggle="yes">S</italic>
<sub>vh</sub> for unfolding and
the emergence of a second thermal denaturation transition.</p><p>The
other variants did not contain significant oligomers in the
starting material, and the progressive truncation from 228TGA to 223TGA
led to changes in aggregation kinetics under forced degrdation conditions
that were nonlinear with hinge length, but that did correlate very
well with their &#916;<italic toggle="yes">S</italic>
<sub>vh</sub> for unfolding,
while their <italic toggle="yes">T</italic>
<sub>m</sub> values remained essentially
unchanged. This behavior was observed previously with point mutations
within the hinge region, and highlights that increased hinge region
flexibility leads to faster aggregation kinetics.</p><p>Variants 228TGA
and 227TGA were the most stable kinetically under
forced degradation conditions, and also contained minimal oligomer
content in the starting material. This indicates that the hinge was
still long enough to protect the nearby cysteine residues from intermolecular
disulfide formation, and also that the removal of the two terminal
alanine residues was important for suppressing aggregation kinetics.
It is possible that these two residues were themselves involved in
enhancing protein&#8211;protein interactions that promote aggregation,
or that their increased structural flexibility induced further structural
dynamics in the local region that could promote aggregation.</p></sec></sec><sec id="sec4"><title>Conclusion</title><p>In this study, we explored the effects of
hinge truncation on the
thermal stability and aggregation propensity of an antibody Fab fragment.
By engineering eight Fab variants with progressively shortened hinge
regions, we demonstrated that truncating the hinge region can significantly
enhance the thermal stability and reduce aggregation. Notably, the
227TGA variant showed the most promising results, with a 14.5% reduction
in aggregation rate compared to the wild type, while maintaining comparable
thermal stability. These findings suggest that hinge truncation is
a viable strategy for improving the developability of therapeutic
antibody fragments, particularly those prone to stability issues.</p><p>Future research should aim to evaluate the impact of hinge truncations
on other measures of stability (agitation, light stress, packaging
interactions), alongside in vivo efficacy and pharmacokinetics, would
also provide valuable insights in future. It would also be useful
in future to demonstrate the generalizability of hinge truncation
to maximize stability and minimize aggregation across a broader range
of antibody fragments. Overall, hinge truncation represents a promising
avenue to explore for other antibody fragments under development as
therapeutics or diagnostics.</p></sec><sec sec-type="supplementary-material"><title>Supplementary Material</title><supplementary-material id="sifile1" position="float" content-type="local-data" orientation="portrait"><media xlink:href="mp5c00358_si_001.pdf" position="float" orientation="portrait"/></supplementary-material></sec></body><back><ack id="ack1"><p>The support of the Engineering and Physical Sciences
Research Council (EPSRC) Centre for Innovative Manufacturing in Emergent
Macromolecular Therapies (EP/I033270/1) and the EPSRC Future Targeted
Healthcare Manufacturing Hub (EP/P006485/1) is gratefully acknowledged.
The Hub is part of the Advanced Centre for Biochemical Engineering,
Department of Biochemical Engineering, University College London.
The authors thank UCB Pharma for providing the Fab A33.</p></ack><notes id="notes1" notes-type="si"><p>The Supporting Information is
available free of charge at <ext-link xlink:href="https://pubs.acs.org/doi/10.1021/acs.molpharmaceut.5c00358?goto=supporting-info" ext-link-type="uri">https://pubs.acs.org/doi/10.1021/acs.molpharmaceut.5c00358</ext-link>.<list list-type="simple" id="silist"><list-item><p>Fab amino acid
sequence; Mass spectra of all Fab variants;
Table of mass spectrometry data for all variants; Table to compare
theoretical and experimental massess of variants; Two-state and three-state
fits for differential scanning fluorescence thermograms; SEC-HPLC
retention times for all Fab variants (<ext-link xlink:href="https://pubs.acs.org/doi/suppl/10.1021/acs.molpharmaceut.5c00358/suppl_file/mp5c00358_si_001.pdf" ext-link-type="uri">PDF</ext-link>)</p></list-item></list>
</p></notes><notes id="notes2" notes-type="conflict-of-interest"><p>The authors
declare no competing financial interest.</p></notes><ref-list><ref id="ref1"><element-citation publication-type="journal" id="cit1"><name name-style="western"><surname>Le
Basle</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Chennell</surname><given-names>P.</given-names></name><name name-style="western"><surname>Tokhadze</surname><given-names>N.</given-names></name><name name-style="western"><surname>Astier</surname><given-names>A.</given-names></name><name name-style="western"><surname>Sautou</surname><given-names>V.</given-names></name><article-title>Physicochemical Stability of Monoclonal Antibodies:
A Review</article-title><source>J. Pharm. Sci.</source><year>2020</year><volume>109</volume><fpage>169</fpage><lpage>190</lpage><pub-id pub-id-type="doi">10.1016/j.xphs.2019.08.009</pub-id><pub-id pub-id-type="pmid">31465737</pub-id></element-citation></ref><ref id="ref2"><element-citation publication-type="journal" id="cit2"><name name-style="western"><surname>Elgundi</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Reslan</surname><given-names>M.</given-names></name><name name-style="western"><surname>Cruz</surname><given-names>E.</given-names></name><name name-style="western"><surname>Sifniotis</surname><given-names>V.</given-names></name><name name-style="western"><surname>Kayser</surname><given-names>V.</given-names></name><article-title>The state-of-play and future of antibody therapeutics</article-title><source>Adv. Drug Delivery Rev.</source><year>2017</year><volume>122</volume><fpage>2</fpage><lpage>19</lpage><pub-id pub-id-type="doi">10.1016/j.addr.2016.11.004</pub-id><pub-id pub-id-type="pmid">27916504</pub-id></element-citation></ref><ref id="ref3"><element-citation publication-type="journal" id="cit3"><name name-style="western"><surname>Saeed</surname><given-names>A. F. U. H.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>R.</given-names></name><name name-style="western"><surname>Ling</surname><given-names>S.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>S.</given-names></name><article-title>Antibody engineering
for pursuing a healthier future</article-title><source>Front. Microbiol.</source><year>2017</year><volume>8</volume><fpage>1</fpage><lpage>28</lpage><pub-id pub-id-type="doi">10.3389/fmicb.2017.00495</pub-id><pub-id pub-id-type="pmid">28400756</pub-id><pub-id pub-id-type="pmcid">PMC5368232</pub-id></element-citation></ref><ref id="ref4"><element-citation publication-type="journal" id="cit4"><name name-style="western"><surname>Ma</surname><given-names>H.</given-names></name><name name-style="western"><surname>&#211;&#8217;F&#225;g&#225;in</surname><given-names>C.</given-names></name><name name-style="western"><surname>O&#8217;Kennedy</surname><given-names>R.</given-names></name><article-title>Antibody stability:
A key to performance - Analysis, influences and improvement</article-title><source>Biochimie</source><year>2020</year><volume>177</volume><fpage>213</fpage><lpage>225</lpage><pub-id pub-id-type="doi">10.1016/j.biochi.2020.08.019</pub-id><pub-id pub-id-type="pmid">32891698</pub-id></element-citation></ref><ref id="ref5"><element-citation publication-type="journal" id="cit5"><name name-style="western"><surname>Lundahl</surname><given-names>M. L. E.</given-names></name><name name-style="western"><surname>Fogli</surname><given-names>S.</given-names></name><name name-style="western"><surname>Colavita</surname><given-names>P. E.</given-names></name><name name-style="western"><surname>Scanlan</surname><given-names>E. M.</given-names></name><article-title>Aggregation of protein
therapeutics enhances their immunogenicity: Causes and mitigation
strategies</article-title><source>RSC Chem. Biol.</source><year>2021</year><volume>2</volume><fpage>1004</fpage><lpage>1020</lpage><pub-id pub-id-type="doi">10.1039/D1CB00067E</pub-id><pub-id pub-id-type="pmid">34458822</pub-id><pub-id pub-id-type="pmcid">PMC8341748</pub-id></element-citation></ref><ref id="ref6"><element-citation publication-type="journal" id="cit6"><name name-style="western"><surname>Hanning</surname><given-names>K. R.</given-names></name><name name-style="western"><surname>Minot</surname><given-names>M.</given-names></name><name name-style="western"><surname>Warrender</surname><given-names>A. K.</given-names></name><name name-style="western"><surname>Kelton</surname><given-names>W.</given-names></name><name name-style="western"><surname>Reddy</surname><given-names>S. T.</given-names></name><article-title>Deep mutational
scanning for therapeutic antibody engineering</article-title><source>Trends Pharmacol. Sci.</source><year>2022</year><volume>43</volume><fpage>123</fpage><lpage>135</lpage><pub-id pub-id-type="doi">10.1016/j.tips.2021.11.010</pub-id><pub-id pub-id-type="pmid">34895944</pub-id></element-citation></ref><ref id="ref7"><element-citation publication-type="journal" id="cit7"><name name-style="western"><surname>Skamaki</surname><given-names>K.</given-names></name><name name-style="western"><surname>Emond</surname><given-names>S.</given-names></name><name name-style="western"><surname>Chodorge</surname><given-names>M.</given-names></name><name name-style="western"><surname>Andrews</surname><given-names>J.</given-names></name><name name-style="western"><surname>Rees</surname><given-names>D. G.</given-names></name><name name-style="western"><surname>Cannon</surname><given-names>D.</given-names></name><name name-style="western"><surname>Popovic</surname><given-names>B.</given-names></name><name name-style="western"><surname>Buchanan</surname><given-names>A.</given-names></name><name name-style="western"><surname>Minter</surname><given-names>R. R.</given-names></name><name name-style="western"><surname>Hollfelder</surname><given-names>F.</given-names></name><article-title>In vitro evolution
of antibody affinity via insertional
scanning mutagenesis of an entire antibody variable region</article-title><source>Proc. Natl. Acad. Sci. U.S.A.</source><year>2020</year><volume>117</volume><fpage>27307</fpage><lpage>27318</lpage><pub-id pub-id-type="doi">10.1073/pnas.2002954117</pub-id><pub-id pub-id-type="pmid">33067389</pub-id><pub-id pub-id-type="pmcid">PMC7959553</pub-id></element-citation></ref><ref id="ref8"><element-citation publication-type="journal" id="cit8"><name name-style="western"><surname>Kim</surname><given-names>J. H.</given-names></name><name name-style="western"><surname>Song</surname><given-names>D. H.</given-names></name><name name-style="western"><surname>Youn</surname><given-names>S.-J.</given-names></name><name name-style="western"><surname>Kim</surname><given-names>J. W.</given-names></name><name name-style="western"><surname>Cho</surname><given-names>G.</given-names></name><name name-style="western"><surname>Kim</surname><given-names>S. C.</given-names></name><name name-style="western"><surname>Lee</surname><given-names>H.</given-names></name><name name-style="western"><surname>Jin</surname><given-names>M. S.</given-names></name><name name-style="western"><surname>Lee</surname><given-names>J.-O.</given-names></name><article-title>Crystal
structures of mono- and bi-specific diabodies and reduction of their
structural flexibility by introduction of disulfide bridges at the
Fv interface</article-title><source>Sci. Rep.</source><year>2016</year><volume>6</volume><fpage>34515</fpage><pub-id pub-id-type="doi">10.1038/srep34515</pub-id><pub-id pub-id-type="pmid">27682821</pub-id><pub-id pub-id-type="pmcid">PMC5041106</pub-id></element-citation></ref><ref id="ref9"><element-citation publication-type="journal" id="cit9"><name name-style="western"><surname>Liu</surname><given-names>J. L.</given-names></name><name name-style="western"><surname>Goldman</surname><given-names>E. R.</given-names></name><name name-style="western"><surname>Zabetakis</surname><given-names>D.</given-names></name><name name-style="western"><surname>Walper</surname><given-names>S. A.</given-names></name><name name-style="western"><surname>Turner</surname><given-names>K. B.</given-names></name><name name-style="western"><surname>Shriver-Lake</surname><given-names>L. C.</given-names></name><name name-style="western"><surname>Anderson</surname><given-names>G. P.</given-names></name><article-title>Enhanced production of a single domain
antibody with an engineered stabilizing extra disulfide bond</article-title><source>Microb. Cell Fact.</source><year>2015</year><volume>14</volume><fpage>158</fpage><pub-id pub-id-type="doi">10.1186/s12934-015-0340-3</pub-id><pub-id pub-id-type="pmid">26449768</pub-id><pub-id pub-id-type="pmcid">PMC4599338</pub-id></element-citation></ref><ref id="ref10"><element-citation publication-type="journal" id="cit10"><name name-style="western"><surname>Jennewein</surname><given-names>M. F.</given-names></name><name name-style="western"><surname>Alter</surname><given-names>G.</given-names></name><article-title>The Immunoregulatory
Roles of Antibody Glycosylation</article-title><source>Trends Immunol.</source><year>2017</year><volume>38</volume><fpage>358</fpage><lpage>372</lpage><pub-id pub-id-type="doi">10.1016/j.it.2017.02.004</pub-id><pub-id pub-id-type="pmid">28385520</pub-id></element-citation></ref><ref id="ref11"><element-citation publication-type="journal" id="cit11"><name name-style="western"><surname>Wang</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Zhu</surname><given-names>J.</given-names></name><name name-style="western"><surname>Lu</surname><given-names>H.</given-names></name><article-title>Antibody glycosylation:
impact on antibody drug characteristics
and quality control</article-title><source>Appl. Microbiol. Biotechnol.</source><year>2020</year><volume>104</volume><fpage>1905</fpage><lpage>1914</lpage><pub-id pub-id-type="doi">10.1007/s00253-020-10368-7</pub-id><pub-id pub-id-type="pmid">31940081</pub-id></element-citation></ref><ref id="ref12"><element-citation publication-type="journal" id="cit12"><name name-style="western"><surname>Vajda</surname><given-names>S.</given-names></name><name name-style="western"><surname>Porter</surname><given-names>K. A.</given-names></name><name name-style="western"><surname>Kozakov</surname><given-names>D.</given-names></name><article-title>Progress toward
improved understanding
of antibody maturation</article-title><source>Current Opin. Struct.
Biol.</source><year>2021</year><volume>67</volume><fpage>226</fpage><lpage>231</lpage><pub-id pub-id-type="doi">10.1016/j.sbi.2020.11.008</pub-id><pub-id pub-id-type="pmcid">PMC8177482</pub-id><pub-id pub-id-type="pmid">33610066</pub-id></element-citation></ref><ref id="ref13"><element-citation publication-type="journal" id="cit13"><name name-style="western"><surname>Lee</surname><given-names>C. C.</given-names></name><name name-style="western"><surname>Perchiacca</surname><given-names>J. M.</given-names></name><name name-style="western"><surname>Tessier</surname><given-names>P. M.</given-names></name><article-title>Toward aggregation-resistant antibodies
by design</article-title><source>Trends Biotechnol.</source><year>2013</year><volume>31</volume><fpage>612</fpage><lpage>620</lpage><pub-id pub-id-type="doi">10.1016/j.tibtech.2013.07.002</pub-id><pub-id pub-id-type="pmid">23932102</pub-id></element-citation></ref><ref id="ref14"><element-citation publication-type="journal" id="cit14"><name name-style="western"><surname>van
der Kant</surname><given-names>R.</given-names></name><name name-style="western"><surname>Karow-Zwick</surname><given-names>A. R.</given-names></name><name name-style="western"><surname>Durme</surname><given-names>J. V.</given-names></name><name name-style="western"><surname>Belch</surname><given-names>M.</given-names></name><name name-style="western"><surname>Gallardo</surname><given-names>R.</given-names></name><name name-style="western"><surname>Seeliger</surname><given-names>D.</given-names></name><name name-style="western"><surname>Abfalg</surname><given-names>K.</given-names></name><name name-style="western"><surname>Baatsen</surname><given-names>P.</given-names></name><name name-style="western"><surname>Compernolle</surname><given-names>G.</given-names></name><name name-style="western"><surname>Gils</surname><given-names>A.</given-names></name><name name-style="western"><surname>Studts</surname><given-names>J. M.</given-names></name><name name-style="western"><surname>Schulz</surname><given-names>P.</given-names></name><name name-style="western"><surname>Garidel</surname><given-names>P.</given-names></name><name name-style="western"><surname>Schymkowitz</surname><given-names>J.</given-names></name><name name-style="western"><surname>Rousseua</surname><given-names>F.</given-names></name><article-title>Prediction and Reduction
of the Aggregation of Monoclonal Antibodies</article-title><source>J. Mol. Biol.</source><year>2017</year><volume>429</volume><fpage>1244</fpage><lpage>1261</lpage><pub-id pub-id-type="doi">10.1016/j.jmb.2017.03.014</pub-id><pub-id pub-id-type="pmid">28322916</pub-id><pub-id pub-id-type="pmcid">PMC5397608</pub-id></element-citation></ref><ref id="ref15"><element-citation publication-type="journal" id="cit15"><name name-style="western"><surname>Sormanni</surname><given-names>P.</given-names></name><name name-style="western"><surname>Amery</surname><given-names>L.</given-names></name><name name-style="western"><surname>Ekizoglou</surname><given-names>S.</given-names></name><name name-style="western"><surname>Vendruscolo</surname><given-names>M.</given-names></name><name name-style="western"><surname>Popovic</surname><given-names>B.</given-names></name><article-title>Rapid and accurate in silico solubility
screening of
a monoclonal antibody library</article-title><source>Sci. Rep.</source><year>2017</year><volume>7</volume><fpage>8200</fpage><pub-id pub-id-type="doi">10.1038/s41598-017-07800-w</pub-id><pub-id pub-id-type="pmid">28811609</pub-id><pub-id pub-id-type="pmcid">PMC5558012</pub-id></element-citation></ref><ref id="ref16"><element-citation publication-type="journal" id="cit16"><name name-style="western"><surname>Li</surname><given-names>W.</given-names></name><name name-style="western"><surname>Prabakaran</surname><given-names>P.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>W.</given-names></name><name name-style="western"><surname>Zhu</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Feng</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Dimitrov</surname><given-names>D. S.</given-names></name><article-title>Antibody Aggregation: Insights from Sequence and Structure</article-title><source>Antibodies</source><year>2016</year><volume>5</volume><fpage>19</fpage><pub-id pub-id-type="doi">10.3390/antib5030019</pub-id><pub-id pub-id-type="pmid">31558000</pub-id><pub-id pub-id-type="pmcid">PMC6698864</pub-id></element-citation></ref><ref id="ref17"><element-citation publication-type="journal" id="cit17"><name name-style="western"><surname>Yu</surname><given-names>L.</given-names></name><name name-style="western"><surname>Huang</surname><given-names>N.</given-names></name><name name-style="western"><surname>Ge</surname><given-names>L.</given-names></name><name name-style="western"><surname>Sun</surname><given-names>H.</given-names></name><name name-style="western"><surname>Fu</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>C.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>J.</given-names></name><article-title>Structural design of
tetravalent T-cell engaging bispecific
antibodies: improve developability by engineering disulfide bonds</article-title><source>J. Biol. Eng.</source><year>2021</year><volume>15</volume><fpage>18</fpage><pub-id pub-id-type="doi">10.1186/s13036-021-00272-7</pub-id><pub-id pub-id-type="pmid">34187511</pub-id><pub-id pub-id-type="pmcid">PMC8243740</pub-id></element-citation></ref><ref id="ref18"><element-citation publication-type="journal" id="cit18"><name name-style="western"><surname>Ulitzka</surname><given-names>M.</given-names></name><name name-style="western"><surname>Carrara</surname><given-names>S.</given-names></name><name name-style="western"><surname>Grzeschik</surname><given-names>J.</given-names></name><name name-style="western"><surname>Kornmann</surname><given-names>H.</given-names></name><name name-style="western"><surname>Hock</surname><given-names>B.</given-names></name><name name-style="western"><surname>Kolmar</surname><given-names>H.</given-names></name><article-title>Engineering therapeutic
antibodies for patient safety:
Tackling the immunogenicity problem</article-title><source>Protein
Eng. Des. Sel.</source><year>2020</year><volume>33</volume><fpage>gzaa025</fpage><pub-id pub-id-type="doi">10.1093/protein/gzaa025</pub-id><pub-id pub-id-type="pmid">33128053</pub-id></element-citation></ref><ref id="ref19"><element-citation publication-type="journal" id="cit19"><name name-style="western"><surname>Niwa</surname><given-names>R.</given-names></name><name name-style="western"><surname>Satoh</surname><given-names>M.</given-names></name><article-title>The current status
and prospects of antibody engineering for therapeutic
use: Focus on glycoengineering technology</article-title><source>J.
Pharm. Sci.</source><year>2015</year><volume>104</volume><fpage>930</fpage><lpage>941</lpage><pub-id pub-id-type="doi">10.1002/jps.24316</pub-id><pub-id pub-id-type="pmid">25583555</pub-id></element-citation></ref><ref id="ref20"><element-citation publication-type="journal" id="cit20"><name name-style="western"><surname>Valeich</surname><given-names>J.</given-names></name><name name-style="western"><surname>Boyd</surname><given-names>D.</given-names></name><name name-style="western"><surname>Kanwar</surname><given-names>M.</given-names></name><name name-style="western"><surname>Stenzel</surname><given-names>D.</given-names></name><name name-style="western"><surname>De Ghosh</surname><given-names>D.</given-names></name><name name-style="western"><surname>Ebrahimi</surname><given-names>A.</given-names></name><name name-style="western"><surname>Woo</surname><given-names>J.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>J.</given-names></name><name name-style="western"><surname>Ambrogelly</surname><given-names>A.</given-names></name><article-title>Taking the
hinge off: An approach to effector-less monoclonal antibodies</article-title><source>Antibodies</source><year>2020</year><volume>9</volume><fpage>50</fpage><pub-id pub-id-type="doi">10.3390/antib9040050</pub-id><pub-id pub-id-type="pmid">32977708</pub-id><pub-id pub-id-type="pmcid">PMC7709103</pub-id></element-citation></ref><ref id="ref21"><element-citation publication-type="journal" id="cit21"><name name-style="western"><surname>Nelson</surname><given-names>A. L.</given-names></name><article-title>Antibody
Fragments: Hope and Hype</article-title><source>MAbs</source><year>2010</year><volume>2</volume><fpage>77</fpage><lpage>83</lpage><pub-id pub-id-type="doi">10.4161/mabs.2.1.10786</pub-id><pub-id pub-id-type="pmid">20093855</pub-id><pub-id pub-id-type="pmcid">PMC2828581</pub-id></element-citation></ref><ref id="ref22"><element-citation publication-type="journal" id="cit22"><name name-style="western"><surname>Chakroun</surname><given-names>N.</given-names></name><name name-style="western"><surname>Hilton</surname><given-names>D.</given-names></name><name name-style="western"><surname>Ahmad</surname><given-names>S. S.</given-names></name><name name-style="western"><surname>Platt</surname><given-names>G. W.</given-names></name><name name-style="western"><surname>Dalby</surname><given-names>P. A.</given-names></name><article-title>Mapping
the Aggregation Kinetics of a Therapeutic Antibody Fragment</article-title><source>Mol. Pharmaceutics</source><year>2016</year><volume>13</volume><fpage>307</fpage><lpage>319</lpage><pub-id pub-id-type="doi">10.1021/acs.molpharmaceut.5b00387</pub-id><pub-id pub-id-type="pmid">26692229</pub-id></element-citation></ref><ref id="ref23"><element-citation publication-type="journal" id="cit23"><name name-style="western"><surname>Zhang</surname><given-names>C.</given-names></name><name name-style="western"><surname>Bye</surname><given-names>J. W.</given-names></name><name name-style="western"><surname>Lui</surname><given-names>L. H.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>H.</given-names></name><name name-style="western"><surname>Hales</surname><given-names>J.</given-names></name><name name-style="western"><surname>Brocchini</surname><given-names>S.</given-names></name><name name-style="western"><surname>Curtis</surname><given-names>R. A.</given-names></name><name name-style="western"><surname>Dalby</surname><given-names>P. A.</given-names></name><article-title>Enhanced Thermal
Stability and Reduced Aggregation in an Antibody Fab Fragment at Elevated
Concentrations</article-title><source>Mol. Pharm.</source><year>2023</year><volume>20</volume><fpage>2650</fpage><lpage>2661</lpage><pub-id pub-id-type="doi">10.1021/acs.molpharmaceut.3c00081</pub-id><pub-id pub-id-type="pmid">37040431</pub-id><pub-id pub-id-type="pmcid">PMC10155210</pub-id></element-citation></ref><ref id="ref24"><element-citation publication-type="journal" id="cit24"><name name-style="western"><surname>Tang</surname><given-names>J.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>C.</given-names></name><name name-style="western"><surname>Castillo</surname><given-names>N. C.</given-names></name><name name-style="western"><surname>Lalaurie</surname><given-names>C. J.</given-names></name><name name-style="western"><surname>Gao</surname><given-names>X.</given-names></name><name name-style="western"><surname>Dalby</surname><given-names>P. A.</given-names></name><name name-style="western"><surname>Kozielski</surname><given-names>F.</given-names></name><article-title>Crystal structures
and molecular
dynamics simulations of a humanised antibody fragment at acidic to
basic pH</article-title><source>Sci. Rep.</source><year>2023</year><volume>13</volume><fpage>16281</fpage><pub-id pub-id-type="doi">10.1038/s41598-023-42698-7</pub-id><pub-id pub-id-type="pmid">37770469</pub-id><pub-id pub-id-type="pmcid">PMC10539359</pub-id></element-citation></ref><ref id="ref25"><element-citation publication-type="journal" id="cit25"><name name-style="western"><surname>Zhang</surname><given-names>C.</given-names></name><name name-style="western"><surname>Codina</surname><given-names>N.</given-names></name><name name-style="western"><surname>Tang</surname><given-names>J.</given-names></name><name name-style="western"><surname>Yu</surname><given-names>H.</given-names></name><name name-style="western"><surname>Chakroun</surname><given-names>N.</given-names></name><name name-style="western"><surname>Kozielski</surname><given-names>F.</given-names></name><name name-style="western"><surname>Dalby</surname><given-names>P. A.</given-names></name><article-title>Comparison of the pH- and thermally-induced
fluctuations of a therapeutic antibody Fab fragment by molecular dynamics
simulation</article-title><source>Comput. Struct. Biotechnol. J.</source><year>2021</year><volume>19</volume><fpage>2726</fpage><lpage>2741</lpage><pub-id pub-id-type="doi">10.1016/j.csbj.2021.05.005</pub-id><pub-id pub-id-type="pmid">34093988</pub-id><pub-id pub-id-type="pmcid">PMC8131956</pub-id></element-citation></ref><ref id="ref26"><element-citation publication-type="journal" id="cit26"><name name-style="western"><surname>Zhang</surname><given-names>C.</given-names></name><name name-style="western"><surname>Samad</surname><given-names>M.</given-names></name><name name-style="western"><surname>Yu</surname><given-names>H.</given-names></name><name name-style="western"><surname>Chakroun</surname><given-names>N.</given-names></name><name name-style="western"><surname>Hilton</surname><given-names>D.</given-names></name><name name-style="western"><surname>Dalby</surname><given-names>P. A.</given-names></name><article-title>Computational-design
to reduce conformational flexibility
and aggregation rates of an antibody Fab fragment</article-title><source>Mol. Pharmaceutics</source><year>2018</year><volume>15</volume><fpage>3079</fpage><lpage>3092</lpage><pub-id pub-id-type="doi">10.1021/acs.molpharmaceut.8b00186</pub-id><pub-id pub-id-type="pmid">29897777</pub-id></element-citation></ref><ref id="ref27"><element-citation publication-type="journal" id="cit27"><name name-style="western"><surname>Codina</surname><given-names>N.</given-names></name><name name-style="western"><surname>Hilton</surname><given-names>D.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>C.</given-names></name><name name-style="western"><surname>Chakroun</surname><given-names>N.</given-names></name><name name-style="western"><surname>Ahmad</surname><given-names>S. S.</given-names></name><name name-style="western"><surname>Perkins</surname><given-names>S. J.</given-names></name><name name-style="western"><surname>Dalby</surname><given-names>P. A.</given-names></name><article-title>An Expanded Conformation of an Antibody
Fab Region by X-Ray Scattering, Molecular Dynamics, and smFRET Identifies
an Aggregation Mechanism</article-title><source>J. Mol. Biol.</source><year>2019</year><volume>431</volume><fpage>1409</fpage><lpage>1425</lpage><pub-id pub-id-type="doi">10.1016/j.jmb.2019.02.009</pub-id><pub-id pub-id-type="pmid">30776431</pub-id></element-citation></ref><ref id="ref28"><element-citation publication-type="journal" id="cit28"><name name-style="western"><surname>Azuaga</surname><given-names>A. I.</given-names></name><name name-style="western"><surname>Dobson</surname><given-names>C.</given-names></name><name name-style="western"><surname>Mateo</surname><given-names>P. L.</given-names></name><name name-style="western"><surname>Conejero-Lara</surname><given-names>F.</given-names></name><article-title>Unfolding
and aggregation during the thermal denaturation of streptokinase</article-title><source>Eur. J. Biochem.</source><year>2002</year><volume>269</volume><fpage>4121</fpage><lpage>4133</lpage><pub-id pub-id-type="doi">10.1046/j.1432-1033.2002.03107.x</pub-id><pub-id pub-id-type="pmid">12180989</pub-id></element-citation></ref></ref-list></back></article>
        
    </metadata>
</record>
    </GetRecord>

</OAI-PMH>